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THE EFFECT OF HLA DPB1 ALLELES ON THE IMMUNE RESPONSE IN 
CHRONIC HEPATITIS B 
SUMMARY 
Chronic Hepatitis B Infection is a global health problem that affects more than 2 
billion people all around the world. Furthermore, more than 400 million people are 
chronic carriers of this virus that can lead to chronic hepatitis, liver cirrhosis and 
hepatocellular carcinoma. Annualy 2 million people die owing to the this virus 
throughout world. In Turkey, it is known that 3 million people suffer from Chronic 
Hepatitis B disease.  
Hepatitis B virus (HBV) is a small DNA virus and is a member of hepadnaviruses 
that includes a partially double-stranded circular DNA containing approximately 
3200 base pairs.  
Once the Hepatitis B virus invades the body, it binds to the cell surface and 
penetrates to the host cells with the help of its envelope proteins. The virus is 
transported in to the nucleus from the plasma membrane of the cell. After that, the 
partially circular DNA is made into covalently closed circular DNA (cccDNA) to be 
used as a template for pregenomic RNA and mRNA. Even though, the negative 
strand of virus is almost a complete circle, the second strand, pozitive strand, is 
shorter in length. The negative strand encodes the structural proteins of the virus 
whereas the pozitive strand  encodes some of the structural proteins and overlaps 
with most parts of the negative strand. Hepadnaviruses depends on reverse 
transcription of negative-strand DNA which is transcribed by the DNA polymerase 
from a “pregenomic” RNA intermediate. Viral proteins are translated by the mRNA, 
then the proteins and genome are packaged into virions and transported out of the 
cell to infect new hepatocytes. 
This potentially life threatining virus is spread by contact with the infected blood, 
unprotected sexual activity, organ transplantation, horizontal, nosocomial injury and 
intravenous drug use. It can also transmitted from mother to infant at birth.  
Furthermore, host genetic factors play a significant role in the pathogenesis. 
Mainly, the aim of the treatment for chronic hepatitis B is to supress viral replication 
and to induce remission before the significant irreversible liver damage. On the other 
hand, the long-term goal of treatment is to eliminate the virus, prevent disease 
xx 
 
progression and to improve patient survival. Interferon and lamivudine are the most 
widely used agents for the treatment of chronic hepatitis B diseases. Other used 
agents are adefovir dipivoxil (ADV), tenofovir disoproxil fumarate (TDF), entecavir 
(ETV) and telbivudine (LdT). 
The human leukocyte antigen (HLA) encodes the major histocompatibility complex 
(MHC) in humans and this region of the genome is critical for inflammation, 
infection and autoimmunity. Studies have shown that HLA class II molecules, which 
show high polymorphism, and cytokines are the susceptibility factors of chronic 
HBV infection. 
Genome-wide association study (GWAS) can methodically investigate hundreds of 
thousands of single nucleotide polymorphisms (SNPs) that are located near HLA loci 
in chromosome 6p21.According to previous studies, GWAS determined candidate 
SNPs of the HLA loci that are related with chronic HBV or HCV infection, hepatic 
fibrosis and hepatocellular carcinoma. Moreover, recent GWAS done on chronic 
hepatitis B infected patients revealed SNPs in HLA class II genes, especially HLA-
DPA1 and HLA-DPB1 region. In this line, our work aims to determine alterations in 
the HLA-DPB1 site of the genome of HBV infected Turkish patients and link these 
possible polymorphisms to disease associations in Turkish population.  
In this study, a total of 94 patients (Group A) were included, from Department of 
Gastroenterology, Goztepe Teaching and Research Hospital. These hepatitis B 
patients who were followed up at hepatology clinic and, age and gender matched 85 
HBsAg negative, anti-HBs positive and anti –Hbc IgG positive spontaneous 
seroconverted healthy subjects (Group B) were enrolled. We also used historical 
controls as Group C by taking disease related information directly from the published 
literature, which includes Turkish and German populations. Group C is used to 
compare HLA-DPB1 frequencies from general population with the disease 
population of this study.  Local ethics committee approval was taken. Genomic DNA 
was extracted from peripheral blood samples. HLA DPB1 alleles were determined by 
restriction fragment length polymorphisms–polymerase chain reaction at medium 
resolution. 9 different restriction endonucleases were selected for digestion to detect 
allele-specific cleavage after PCR-amplification of the DPBl alleles.The distribution 
of the alleles among patients and control subjects were analyzed. 
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Among the 19 analyzed DPB1 alleles in this study, DPB1*02:01 was the most 
prevalent (genotyped in 30.2% of patient and control groups). DPB1*15:01 allele 
was more frequent in the spontaneous seroconverted control group compared to 
chronic hepatitis B patients (15.3% vs. 1.1%, χ2=12.5, OR=0.06, 95% CI=0.08-0.046 
p<0.001,pc<0.001). DPB1*02:01 and DPB1*10:01 were the other alleles genotyped 
more frequently found in the control group (38.8% vs. 22.3% p=0.02 and 16.5% vs. 
5.3% p=0.02, respectively). However these two alleles’ associations lost their 
significance after Bonferoni’s correction (pc=0.4 for all).HBsAg seroconversion is 
the ultimate target in chronic hepatitis B. This study revealed an association of HLA 
DPB1*15:01 allele with spontaneous HBsAg seroconversion. However, after 
Bonferroni correction, only DPB1*1501 maintained its significance. It can be said 
that, presence of DPB1*1501 was the protective allele at Turkish population just 
looking at the above data without Hardy Weinberg Analysis.  
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KRONİK HEPATİT B HASTALIĞINDA HLA DPB1 ALLELERİN 
HASTALIĞIN İMMUN YANITA ETKİSİ 
 
ÖZET 
Kronik Hepatit B hastalığı evrensel bir sağlık problemidir. Hepatit B hastalığına 
sebep olan Hepatit B virüsünün, tüm dünyada 2 milyardan fazla kişiyi enfekte ettiği 
bilinmektedir. 400 milyondan fazla kişi ise kronik olarak hepatit B taşıyıcısıdır ve bu 
taşıyıcılık, kronik hepatit başta olmak üzere, karaciğer kanseri ve karaciğer sirozunun 
oluşmasına sebep olabilmektedir. Yıllık olarak bakıldığında tüm dünyada, 2 milyon 
kişinin bu virüsten dolayı hayatlarını kaybettiği kayıtlara geçmektedir. Türkiye’de ise 
yaklaşık 3 milyon kişinin bu hastalıkla mücadele ettiği biliniyor.  
Hepatit B virüsü küçük bir DNA virüsüdür ve yaklaşık olarak 3200 baz çiftine 
sahiptirler. Hepatit B virüsü Hepadonovirus ailesinin bir üyesidir ve kısmi olarak çift 
sarmallı, dairesel DNA içerir. 
Genom üzerinde 4 tane protein kodlayacak nükleik asit dizisi vardır. Bunlar S, C, X 
ve P bölgeleri olarak adlandırılan yüzey, kor, X ve polimeraz proteinleridir. C geni, 
HBcAg proteinlerini kodlar ve bu kor nükleokapsid oluşumuna sebep olan yapısal 
proteinleri içerir. Bu proteinler HBeAg antijenine translasyon sonrası dönüşür. S 
genini içeren Pre S1 ve Pre S2 yüzey proteinleri HBsAg anijenlerini kodlar. P geni 
DNA polimerazı kodlayan protein, ters transkripsiyon aktivitesine sahiptir ve son 
olarak X geni hücrenin potansiyel transaktivatörüdür. X geninin görevi ise tamamen 
bilinmemektedir. Genom üzerinde, 6 başlangıç kodonu, 4 promotör ve 2 tane 
hızlandırıcı element bulunmaktadır. 
Hepatit B virüsünün tüm genomik sekansının üzerinde 8 genotipi tanımlanmıştır ve 
bunlar A’dan H’ye kadar düzenlenmiştir. Bağlantılı olarak, HBV’nin alt tipleri (adw, 
adr, ayw ve ayr) de mevcuttur. A’dan H’ye düzenlenen bu 8 genotip farklı coğrafik 
bölgelerde yayılım göstermiştir. 
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Hepatit B virüsü konak hücreye invaze olduğu zaman, hücre yüzeyine bağlanır ve bu 
hücreye kendi zarf proteinleri yardımıyla girer. Virüs, hücrenin plazma 
membranından nükleusa taşınır. Bu şekilde nükleusa giren virüs kısmen sirküler 
formdan sirküler DNA (cccDNA) formuna dönüşerek öncül RNA ve haberci 
RNA’ya kalıp oluşturur. Virüsün negatif zinciri neredeyse tamamen halkasal yapıda 
olmasına rağmen, pozitif zincirin uzunluğu daha kısadır. Negatif zincir virüsün 
yapısal proteinlerini kodlarken, pozitif zincir bazı yapısal proteinleri kodlar. 
Translasyon sonucu oluşan viral proteinler nükleokapsid içinde toplanır ve 
paketlenir. Daha sonra yeni hepatositleri işgal etmek üzere sitoplazmadan salınır. 
Hayatı tehdit eden bu virüsün bulaşma yolları şu şekildedir: Enfekte olmuş kan 
temasları, korunmasız olarak yapılan cinsel aktivite, organ nakilleri, yatay olarak 
meydana gelen bulaşma, hastane yaralanmaları ve intravenöz ilaç kullanımı olarak 
özetlenebilir. Ayrıca bu hastalık anneden bebeğe doğum esnasında da geçebilir. 
Yapılan çalışmalar, hepatit B virüs enfeksiyonunun progresyonunda sadece viral 
genotip ve vireminin değil, aynı zamanda konak genetik faktorlerinin de oldukça 
önemli rol oynadığını göstermiştir. Aynı zamanda, hem hücresel hem de hümoral 
immün yanıtın virüsün eredike edilmesi için gerekli olduğu birçok deneysel 
çalışmada gösterilmektedir. 
Temel olarak kronik hepatit B hastalığının tedavisinin amacı, viral replikasyonu 
baskılamak ve geri dönülemez karaciğer zararlarını en aza indirgemektir. Öte 
yandan, uzun süreli tedavinin amacı ise virüsü elimine ederek hastalığın 
progresyonunu önlemek. İnterferon ve lamuvidin kronik Hepatit B hastalığının 
tedavisinde kullanılan yaygın ajanlardır. Tedavide kullanılan diğer ajanlar ise 
adefovir dipivoksil (ADV), tenofovir disoproksil fumarat (TDF), entecavir (ETV) 
and telbivudin(LdT)dir. 
Kromozomun 6p21.3 bölgesinde yer alan yüksek derecede polimorfik insan lökosit 
antijen (HLA) geni immün yanıtla çok yakından ilişkilidir.Ayrıca bu polimorfik 
bölge inflamasyondan, enfeksiyondan ve otoimmüniteden de sorumludur. 
Genomun tarandığı (genome wide association-GWA) çalışmalar kromozomun 6p21 
noktasının yakınında bulunan insan lökosit antijende ki, binlerce tek nükleotid 
polimorfizmini ortaya çıkartmıştır. Daha önceki çalışmalara göre HLA lokusunda 
bulunan ve kronik HBV, HCV, hepatik fibroz ve gelişen karaciğer kanser 
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hücreleriyle bağlantılı olabilen aday tek nükleotid polimorfizmleri belirlenmiştir. 
Genomun tarandığı çalışmalarda HLA-DPB1 gen bölgesinin Hepatit B hastalığı ile 
ilişkili olabileceği üzerine veriler elde edilmiştir. Bu bölgenin polimorfik bir bölge 
olmasından dolayı Hepatit B hastalarında hastalık direncine bakarak DPB1 allel 
tayini yapmak ve elde edilecek verilere göre allellerin hastalık için direnç ya da 
yatkınlıklarını incelemek bu çalışmanın temel amacıdır.Biz bu çalışma ile Türk 
populasyonunda, Hepatit B hastalığının immün yanıtta önemli bir rol oynayan HLA 
sınıf II bölgesi genlerinden HLA-DPB1 polimorfizmleri ile ilişkisini araştırarak, 
aday alellerin ve koruyucu alellerin belirlenmesini hedefledik. 
Bu çalışma 94 hasta içermektedir. Bu hastalar Göztepe Eğitim ve Araştırma 
Hastanesi’nde hepatoloji kliniğinden takipli hastalardır. Yaş ve cinsiyetle eşleşmiş 85 
HBsAg negatif, anti- HBs  pozitif ve anti-Hbc IgG spontan serokonverted pozitif 
hastalar katılmıştır. Yerel etik kurulu onayı alınmştır. Kan örneklerinden genomik 
DNA izolasyonu sonucu HLA-DPB1 bölgesine spesifik primerler ile istenilen bölge 
polimeraz zincir reaksiyonu (PZR) ile çoğaltılmıştır. Bu çalışmanın ardından PZR-
RFLP (Restriction Fragmen Length Polimorpism) metodu uygulanarak restriksiyon 
enzimi ile kesim gerçekleştirilir. Bu çalışmada 9 farklı restriksiyon endonukleaz 
kullanılmıştır: Bunlar, Bsp12861, FokI, DdeI, BsaJI, BssHII, Cfrl31, RsaI, EcoNI ve 
AvaII’dir. Restriksiyon enzim kesiminden sonra kesim bölgeleri incelenerek, allel 
tayini yapılmıştır. 
Çalışmaya 94 kronik hepatit B hastası (Grup A) alınmıtır. Bu hastalar Göztepe EAH 
karaciğer hastalıkları polikliniğinde kayıtlı 6 aydan uzun süredir serum HBsAg 
(hepatit B yüzey antijeni) pozitif olan hastalardır. Hastaların ortalama yaşı 47,9±14,7 
dir. Hastaların %61.7’si (n=58) erkek, %75,5 (n=71) HBeAg (hepatit B early 
antigen) negatiftir. Hastaların %57,4(n=54) ‘e karaciğer biopsisi yapılmıştır, Biyopsi 
yapılan hastalarda HAI (hepatik aktivite skoru) 6,5 ±3,3 Fibroz skoru 2±1,5 dir. 
Hastaların %21,3’ünde (n=20) karaciğer sirozu mevcuttur, %83’ü(n=78) hepatit B’ye 
yönelik tedavi almaktadırlar. Ortalama serum ALT düzeyleri 102,1±113, AST 70±96 
dir. Hastaların ortalama izlem süreleri 76 ±52 aydır. 
Kontrol grubu olarak (Grup B) hepatit B geçirmiş, spontan HBsAg serokonversiyonu 
olmuş sağlıklı kişiler alınmıştır (HBsAg negatif, Anti HBs pozitif, Anti HBcIgG 
pozitif). Kontrol grubunda erkek oranı %54 yaş ortalaması 54±13. 
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Hastalıkla ilişkili olduğu düşünülen daha önce yapılmış çalışmalardan, Türk ve 
Alman populasyonlarından oluşan tarihsel kontrol (Grup C) olarak adlandırılan  
çalışma grubunu  inceledik. Bu çalışma grubu Hepatit B hastalığıyla ilintili olan 
populasyonlarda HLA-DPB1 frekansını karşılaştırmak için kullanıldı.  
Analizi yapılan 19 DPB1 alelinde, DPB1*15:01 aleli, kontrol grubunda hepatit B’ye 
sahip olan hastalara göre daha fazla gözlemlenmiştir. DPB1*02:01 ve DPB1*10:01 
ise kontrol grubunda fazla görülen diğer alellerdir. Bu iki alel Bonferoni 
düzeltmesinden sonra önemini kaybetmiştir. Sadece DPB1*15:01 aleli p<0,05 den 
küçük olduğu için önemini sürdürmeye devam ettirmiştir. Türk populasyonunda 
Hardy Weinberg analizi yapılmadan DPB1*15:01 alelinin hepatit B hastalığına karşı 
koruyucu özelliğe sahip olduğunu söyleyebiliriz. 
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1. INTRODUCTION 
1.1 Purpose of the Thesis 
Human Leukocyte antigens are highly polimorphic region (Chien et al., 2010).  
Our study, in this line, is concentrated on host immune response of chronic hepatitis 
B virus infection to analyze the association of human leukocyte antigen class II 
molecules (HLADPB1 Alleles) with the clinical outcome of chronic HBV infection 
in Turkish population. 
In this line, our work aims to determine alterations in the HLA-DPB1 site of the 
genome of HBV infected Turkish patients and link these possible polymorphisms to 
disease associations in Turkish population. 
Findings from this thesis, in general, aim to understand the relationship between 
immunopathogenesis of chronic hepatitis B infection and HLADPB1 Alleles. 
1.2 Chronic Hepatitis B Disease 
Hepatitis B virus (HBV)  is a non-cytopathic hepatotropic viral pathogen (Chang et 
al.,2007). Also, Chronic Hepatitis B virus (HBV) infection is apotentially life-
threatening liver infection worldwide, and approximately two billion people get 
infected with HBV (Huang et al., 2013). Additionally, more than 370 million people 
are chronic carriers of this virus that can lead to chronic hepatitis, hepatocellular 
carcinoma and liver cirrhosis (Ozaslan et al., 2007; Chenet al., 2013; Ciftci S et al., 
2012). Many epidemiological and molecular studies have shown thatHBV infection 
is one of the most significant infectious diseases throughout the world  (Mauss et al., 
2013). Annualy, almost 1.2 million people die owing to the acute or chronic 
consequences of hepatitis B and HBV-related chronic liver diseases (Huang et al., 
2013,Ishikawat et al., 2012). 
According to the World Health Organization (WHO), approximately 54 billion 
people are infected with the hepatitis B virus (HBV) and more than 240 million are 
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chronic hepatitis patients (Xu et al., 2013). Recent studies have shown that nearly 3 
million people have been infected with HBV in Turkey (Tozun et al., 2012). 
The progression rate from acute to chronic HBV infection reduces with age. For 
perinatally, the risk of Hepatitis B virus infection rate is nearly 90%, whereas for 
adults the risk of HBV infection rate is about 5% or even lower (Mauss et al., 2013)   
Viral recovery or persistence factors depend on age at infection, immunodeficiency 
states, gender and host genetic variation (Thomas et al., 2012).The natural history 
and clinical outcomes of chronic HBVinfection are determined by the viral 
replication cycle and the host immune response (Pramoolsinsup., 2002). Both viral 
factors and host immune response have been involved in the pathogenesis and 
clinical outcome of HBV infection (Baumert et al., 2007). 
1.3 Genome Organization of Hepatitis B Virus 
Hepatitis B virus (HBV), a member of hepadnaviruses is the smallest DNA virus 
whole the other animal viruses. The hepatitis B virus is classified as the type species 
of the Orthohepadnavirus. There are three different particule types of Hepatitis B 
virus; the infectious virions and the subviral particles (Tamori et al., 2013) (Figure 
1.1). 
 
 
Figure 1.1 : Particules of Hepatitis B virus showing three different shapes 
(HBV virion and non-infectious empty subviral particles (filaments and spheres) 
(Mauss et al., 2013) 
The infectious virus particles are the so-called Dane particles, have a spherical, 
double shelled structure of 42-44 nm containing a single copy of the viral DNA 
genome. Also there are two additional types of particles, the spheres and the 
filaments,which are exclusively composed of hepatitis B surface proteins and host-
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derived lipids (Tamori et al., 2013). The subviral particles are non-infectious because 
they do not contain viral nucleic acids. 
HBV includes a partially double stranded circular DNA of approximately 3200 base 
pairs for the genome organization. The small Hepatitis DNA virus contains a 
nucleocapsid that consists of HBsAg proteins. There are three various protein 
Hepatitis surface antigen; L, M and S. These are on the same sequencing. The 
surface proteins are named the preS1 (or large), the preS2 (or middle) and the S (or 
small), which correspond to the HBsAg. These surface antigens play a significant 
role in the identification of HBV infection (Baumert et al., 2007). 
The small genome encodes for four main genes by a series ofoverlapping reading 
frames (ORF) (Figure 1.2). 
 
 
 
Figure 1.2:Genome Organization of Hepatitis B virus(adopted from, 
http://commons.wikimedia.org/wiki/File:HBV_genome.png) 
The C gene is divided into a core and a precore region by 2 in-frame initiating AUG 
start codons. While the core region codes the structural protein of the nucleocapsid-
HBcAg, the precore region codes the HBeAg. The function of nucleocapsid protein 
is to enclose the viral DNA and the DNA polymerase that is essential for HBV 
replication (Tan et al., 2008; Shi et al., 2009; Chang et al., 2007)  
The S gene codes for the surface antigen (HBsAg)  that encodes 3 polypeptides of 
the surface antigen (preS1, preS2 and S) produced from the alternative translation 
start sites (Figure 1.2). The most significant part of HBV genome among the four 
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ORFs (C, P, X and S genes), is the HBsAg gene, because the S protein product 
consists of an epitope that generates a protective immune response against the virus ( 
Perillo et al., 2009; Schaefer et al., 2007; Chotiyaputta et al., 2009) 
The gene P also known as HBV polymerase is an enzyme that enables the synthesis 
of DNA using either RNA or DNA templates. Furthermore the gene P includes 
reverse transcriptase activityand its RNase H activity provides the degradation of the 
RNA strand of RNA-DNA hybrids, and the packaging of the RNA pregenome into 
nucleocapsids (Hepatitis B Fact sheet 2008; Perillo et al., 2009). 
The X gene is a transactivator of viral transcription and is thought to display a 
siginificant role in hepatocellular carcinoma (HCC) development. Also, its 
contribution to tumor invasion and metastasis in the course of HBV infection has not 
been established (Schaefer et al., 2007; Coash et al., 2009) 
 
 
Figure 1.3 : Replication form of Hepatitis B virus (Jayalakshm et al., n.d) Upon hepatocyte 
infection the nucleocapsid is released into nucleus where it is converted into the cccDNA. 
After transcription of the viral RNAs, the pgRNA is encapsidated. Through Golgi and ER, 
newly synthesized HBV DNA transported out of the cell. 
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Once the Hepatitis B virus invades the body, it binds to the cell surface and 
penetrates to the host cells with the help of its envelope proteins. The virus is 
transported to the nucleus fromthe plasma membrane of the cell. After that, the 
partially circular DNA is made into covalently closed circular DNA (cccDNA) to be 
used as a template for pregenomic RNA and mRNA. Even though, the minus strand 
of virus is almost a complete circle, the second strand, plus strand, is shorter in 
length. The minus strand encodes the structural proteins of the virus whereas the plus 
strand encodes some of the structural proteins and overlaps with most parts of the 
minus strand. Hepadnaviruses depends on reverse transcription of minus-strand DNA 
which is transcribed by the DNA polymerase from a “pregenomic” RNA 
intermediate. Viral proteins are translated by the mRNA, then the proteins and 
genome are packaged into virionsand transported out of the cell to infect new 
hepatocytes(Vierling et al.,2007; Bertoletti et al., 2005; Das et al., 2010;Özacar et 
al., 2008) (Figure 1.3). 
1.3.1 Associations between HBV genotypes and mutations and their effect on 
clinical outcome 
During viral replication due to the lack of proofreading activity of the viral 
polymerase, misincorporation of nucleotide mutations occur. This has led to the 
emergence of eight HBV genotypes and have been distinguished as A to H, 
according to overall nucleotide sequence variation. There are 9 HBsAg subtypes (4 
major HBsAg subtypes, adw, adr, ayw and ayr) based on their antigenic determinants 
of the surface antigen and HBV genotypes.  
Table 1.1 : Geographic distribution of HBV genotypes and the major serological 
subtypes (Tan et al., 2008) 
 
HBsAg Subtype  Geographical Distribution  
A adw2, ayw1  USA, Northwestern Europe, Africa, India 
B adw2, ayw1  China, Indonesia, Taiwan, Japan 
C 
adw2,adrq+, adrq-, ayr, 
adr  
East Asia, China, Korea, Japan, Vietnam, USA 
Australian,  
D ayw2, ayw3, ayw4 
East Asia, China, Korea, Japan, Vietnam, USA 
Australian,  
E ayw4  West Africa  
F adw4q, adw2, ayw4  Central and South America, Polynesia, 
G adw2 Central America, France, USA, Germany 
H adw4 Central and South America 
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The HBV genotypes and serological subtypes have a distinct global geographical 
distribution (Tan et al., 2008; Chang et al.,2007;Locarnini  2008) (Table 1.1). 
All genotypes have the potential to infect individuals, leading chronic infection with 
various stages of progressive liver disease including cirrhosis and hepatocellular 
carcinoma as well as death. Disease progression and incidence of advanced liver 
diseases, affected by environmental, host and viral factors, may also be different 
according to each HBV genotype. 
For instance, Genotype C and D are, generally, associated with more severe liver 
disease than B and A. Studies showed that HBV genotype A infected patients have a 
higher rate of clearance for HBsAg and HBV DNA as well as biochemical remission 
than either genotype D or F. HBV genotype C infected patients’ biopsies showed 
more advanced fibrotic liver disease and a higher incidence of cirrhosis compared to 
genotype B pathogenic differences among HBV genotypes (Tan et al., 2008).  
Groups of mutations have been defined to reduce or block expression of HBeAg. 
According to the ORFs, gene mutations are summarized: C gene mutations may 
result in inability to produce HBeAg. HBeAg – negative variants are common for 
genotypes D as observed in Turkish population in the pre-core region. (Bertoletti et 
al., 2005; Coash et al., 2007; Chotiyaputta et al., 2009). 
S gene mutations in the HBV surface protein are responsible for the failure of 
immune prophylaxis in infants. Also these mutations enabled the escape from host 
immunity (Perillo et al., 2009; Chotiyaputta et al., 2009).  
 
 
 
Figure: 1.4 : Characterized domains of HBV Polimerase (adopted from 
http://www.clinicaloptions.com) 
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The largest ORF in the HBV genome, which encodes for the hepatitis B polymerase 
protein (P gene), has four domains; a terminal protein (the N-terminus portion of the 
protein acts in priming (-) DNA strand synthesis and ends up covalently linked to the 
5' end of the (-) DNA strand, and termed primase), a spacer region (no enzymatic 
function, just acts as a spacer between the first and third domains), a reverse 
transcriptase (encodes for the RNA and DNA dependent polymerase activity) and an 
RHase H (possesses its RNase H activity) domain (Figure 1.5) (Stchaefer et al., 
2007). 
Table 1.2 HBV mutations and their potential impact for HBV infection pathogenesis 
(Thomas et al., 2007).  
HBV 
region Mutation 
Molecular 
phenotype Clinical relevance  
        
Pre-S/S 
Pre-S1 / Pre-
S2/ Misassembly 
Fibrosing 
cholestatic  
  S- Promoter   hepatitis 
  S Alteration of B and Vaccine escape 
  S splicing T cell epitopes Immune escape 
      Diagnostic escape 
        
Pre-C Pre-C-stop Loss of HBeAg Severe hepatitis 
      HBeAg- deficiency 
Core Core Alteration of T-cell Viral persistance 
    epitopes Severe hepatitis                                                                                
        
RT/Pol Pol 
Replication 
deficieny Viral latency 
      Viral persistence 
  Pol 
Resistance to 
antivirals Therapy escape 
        
Regulatory Core promoter 
Enhanced 
replication Severe hepatitis 
Elements   and core expression Modulation of         
      drug resistance 
    Decreased HBeAg HBeAg 
    Synthesis seronegativity 
  Enhancer I 
Decreased 
replication Chronic hepatitis 
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X gene mutations can affect DNA repair, cell cycle control and apoptosis (Coash et 
al., 2008) because X gene affects the control of transcription by acting as a 
transactivator of various viral and cellular promoter/enhancer factors. Also, 
mutations in this region can activate signal transduction pathways, but the clinical 
significance of HBx mutations are not clearly understood yet (Stchaefer et al., 2007; 
Coash et al., 2008). 
HBV mutations and their potential impact for HBV infection pathogenesis are 
summarized in Table 1.2. The naturally occurring mutations in the context of various 
genotypes have been identified in the structural and non-structural genes as well as 
regulatory elements in the virus. The best characterized mutants are the pre-core 
(pre-C) stop codon mutations resulting in loss of HBeAg, core promoter mutations 
resulting in enhanced viral replication, the mutations in the reverse transcriptase / 
polymerase genes resulting in resistance to antivirals, and mutations in the HBV 
surface gene resulting in alteration in the antigenicity of the viral surface proteins 
(HBsAg) and structure of the viral envelope (Thomas et al., 2007). 
1.4 Epidemiology of HBV 
1.4.1 Transmission of HBV infection 
Hepatitis B virus (HBV) is spread by contact with the infected blood, unprotected 
sexual activity, organ transplantation, horizontal, nosocomial injury and intravenous 
drug use.It can also be transmitted from mother to infant at birth and  leads to acute 
or chronic necroinflammatory liver diseases (Mauss et al., 2013; Ishikawat et al., 
2012; Wang et al., 2010). 
Transmission mode strongly correlates with geographic areas. For instance, Western 
Europe is a low prevalence areas, unprotected sexual intercourse and intravenous 
druguse are main cause disease for the transmission.Sub-Saharan Africa is a high 
prevalence area, perinatal infection is considered as the major route of transmission. 
In intermadiate prevalence areas, especially in early childhood, horizontal 
transmission is regarded the prevalent way ofdiffusion (Mauss et al., 2013). 
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1.4.2 HBV infection worldwide 
Annually, around one million people who suffer from  HBV, die of HBV and related 
diseases. In different areas in the World, HBV has a wide range of prevalence from 
0.1% up to 20%.Low prevalenceareas which is the range of 0.1-2% include 
Australia, United States, Canada, New Zealand and Western Europe; Mediterranean 
countries such as Japan, Central Asia, the Middle East and Latin and South America 
are the intermediate prevalence areas which are the rates of 3-5% and lastly high 
prevalence areas the rates of 10-20%, are mainly China, Southeast Asia and Sub-
Saharan Africa (Mauss et al., 2013). This diversity depends on the risk of chronicity 
and differences in age at infection. 
This epidemiological difference is related with divergence in virtualperiodof 
infectious virus, primary site of viral infection and maturity of the immune system.  
In Asia, both host and viral factors can be effective for the initation of HBV infection 
(Ishikawat et al., 2012;Mauss et al., 2013). 
1.5 Immunopathogenesis of Chronic Hepatitis B Virus Infection 
Innate immunity involves nonspecific responses to pathogens. It is present before 
any exposure to pathogens and is effective from the time of birth (Campbell and 
Reece, 2005). Following HBV infection, inital stages of hepatitis may be 
symptomatic. The mechanism of HBV persistence is not fully understood. Succesful 
clearance and  resolution of infection link to age and immune status of the individual. 
Both cellular and humoral immune responses are important for the chronic HBV 
infection (Campbell and Reece, 2005). 
Following infection with HBV, Hepatocytes release IFN-α and IFN-β. Because 
hepatocytes have low expression of human leukocyte antigen (HLA) class I. IFN-
α/βactivates the antigen presenting cells (APCs), especially, Kupffer cells 
(macrophages that reside in the liver) and dendritic cells (DCs). These APCs produce 
interleukin-18 (IL-18) and the chemokine CCL3which stimulates natural killer (NK) 
and natural killer T (NKT) cell activity (Figure 1.5) (Chang et al., 2007). In HBV 
transgenic mice models, IFN-γ producing NKT cells can directly inhibit HBV 
replication. Recent studies have shown that NK cells, NKT cells and Kupffer cells 
play a significant role in the initial response against HBV (Glebe.,2007) (Chang et 
al., 2007) 
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Adaptive immune response, involves a very specific response to pathogens. It is 
activated in many ways, such as through cytokines and involves the activity 
oflymphocytes. Humoral and cell-mediated immunity defend against different types 
of threats. Adaptive immunity includes two branches; the humoral immune response 
involves the activation and clonal selection of B cells, resulting in the production of 
secreted antibodies andthe cell-mediated immune response involves the activation 
and clonal selection of cytotoxic T cells. Both make signaling reactions (Campbell 
and Reece, 2005). 
In  patients with chronic HBV infection, the HBV-specific CD4+ and CD8+ T-cell 
response is decreased significantly.HBV-specific CD8+ T-cells are found in the liver 
where they may cause an inflammatory response because they have low 
responsiveness to produce IFN-γ especially in HBeAg-positive chronic carriers. 
They are almost undetectable. In some persistent HBV infection have known as 
partially tolerant (Chang et al., 2007) (Glebe.,2007). 
HBV-infected dendritic cells might cause CD4+ T-cell ‘hyporesponsiveness’. Also, 
DCshave limited IFN-γ,TNF- αand IL-12 production (Chang et al., 2007) 
(Glebe.,2007). 
CD25+ CD4+ T-cells which are known regulatory T-cells, are also inhibit of 
proinflammatory responses to reduce immune modulated damage. They may limit 
clearance in other chronic viral infections by suppressing proliferation of virus-
specific CD8+ T-cells (Glebe.,2007). This regulatory T-cell activity reduce 
production of antiviral cytokines such as IFN-γTNF- αin HBV. There is an increase 
or decrease in CD25+ CD4+ T-cells in peripheral blood as compared to uninfected 
healthy controls (Chang et al., 2007). 
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Figure 1.5 : Immunopathogenesis of Hepatitis B virus (taken from Chang et al., 
2007). 
1.6 Treatment of HBV Infection 
In generally, the aim of the treatment for chronic hepatitis B is to supress viral 
replication, eliminate the virus, prevent disease progression and  improve patient 
survival (Pramoolsinsup et al., 2002). 
Although, many drugs have been effectively used in the treatment of chronic 
hepatitis B, interferon and lamivudine are the most widely used agents for the 
treatment of chronic hepatitis B disease (Pramoolsinsup et al., 2002). Interferon 
(today pegylated form is used as apotent drug), which play as reverse transcriptase 
inhibitor of the HBV polymerase, has a direct antiviral effect. Lamivudine, a 
nucleoside analog, advanced HBV-induced liver disease is a potent inhibitor of HBV 
replication. The other nucleotide analogs adefovir dipivoxil (ADV) and tenofovir 
disoproxil fumarate (TDF) are active on the priming of reverse transcription as well 
as on elongation of viral minus strand DNA. Entecavir (ETV) inhibits both minus 
and plus strand DNA synthesis.  Telbivudine (LdT) inhibits all of these three enzyme 
activities (Chen et al., 2013; Locarnini et al., 2008). These medications perform 
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mainly by blocking reverse transcription of the pregenomic RNA to HBV DNA ( 
Chotiyaputta et al., 2009; Gerlich et al., 2013).  
1.7 Human Leukocyte Antigen (HLA) 
The human leukocyte antigen (HLA) is the major histocompatibility complex (MHC) 
in humans that contains most significant region in the human genome with respect to 
inflammation, infection and autoimmunity (Kaufman et al., 1999; Tamori et al., 
2013). Human leukocyte antigen (HLA) presents virus antigens to immune cells that 
is reliable for the clearance of virus-infected cells (Jiang et al.,2013). Genes in this 
complex  fall into three groups: class I, class II, and class III where the HLA region 
located on the short arm of chromose 6 (6p21.1 to p21.3) (Figure 1.9) (Tamori et al., 
2013; Klein et al., 2000). This region contains many other immune response genes 
and it is important in the regulation of the immune response (Taştan et al., 2004; 
Godkin et al., 2005). 
Figure 1.6 :Location and Organization of the HLA Complex on Chromosome 6 
(Mehra et al, 2003) 
The HLA class I known as HLA-A, HLA-B, and HLA-C code for the α polypeptide 
chain of the class I molecule (Klein et al., 2000) (Figure 1.6). Class I genes are 
expressed by largely somatic cells  (Klein et al., 2000). There are 3 major MHC class 
II proteins encoded by the HLA known as class IIHLA-DR, HLA-DQ, and HLA-DP 
(Gebeet al., 2002). These genes provide codes for making proteins that are present 
almost exclusively on the surface of certain immune system cells, specifically on 
antigen-presenting cells. Class II genes, specifically, are expressed in B cells, 
activated T cells, macrophages, dendritic cells, and thymic epithelial cells. Proteins 
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contain α and β chains, both of which are quite polymorphic (Toh et al., 2000; Marsh 
et al., 2010) (Figure 1.7). Each HLA subtype has a specific binding motif that 
dictates the specific range of peptides that can physically bind in a groove on the 
surface of HLA genes (Godkin et al., 2005; Klein et al., 2000). For instance, HLA 
class II genes are expressed as cell surface glycoproteins that bind and present 
peptide epitopes to CD4+ T cells, resulting in their activation.  
 
Figure 1.7 : Structure of HLA Class I and Class II Molecules (Adopted from, 
http://journals.cambridge.org/fulltext) 
HLA loci on chromosome 6 involves three letters: the first (D) implies the class, the 
second (M, O, P, Q, or R) the family, and the third one (A or B) implies the chain (α 
or β, respectively). For instance, HLA-DPB represents class II genes of the P family 
coding for the β chains. Effective presentation of viral antigens to CD4+ T cells and 
CD8+ T cells by HLA class Ⅱ and classⅠmolecules respectively, is responsible 
against viral infection, and additional controls viral clearance or persistence (Jiang et 
al., 2013; Singh et al., 2007). Class III genes implicated in inflammation and other 
immune-system activities (Klein et al.,  2000). 
Besides, HLA class I presents 15 peptides to the cytotoxic T cells with the receptors 
on the cytotoxic T cells, also binds inhibitory receptors on NK cells, hence stimulates 
immune responses against ‘endogenous’ antigens (Klein et al., 2000). Whereas, HLA 
class II molecules stimulate the presentation of ‘exogenous’ antigens to T helper 
cells. Proteosomes degrade worn-out or defective proteins into peptides in the 
cytosol (Klein et al., 2000). 
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HLA-DP is an HLA class II heterodimeric molecule expressed on antigen presenting 
cells (APC), including B cells, dendritic cells, and macrophages, where it functions 
by presenting extracellular antigens to CD4+T cells (Godkin et al., 2005). Also 
HLA-DP contains alpha and beta chains which are encoded by the HLA-DPA1 and -
DPB1 genes, respectively (Lok et al., 2007; Vermehren et al., 2012). 
In the HLA-DP region, there are two DPα and two DPβ genes, arranged in the order: 
DPβ2, DPα2, DPβ1, DPα1. The two pairs of α and β genes have their promoter ends 
adjacent: DPβ1 with DPαl; and a larger distance, DPβ2 and DPα2. The DPα2 and DP 
β2 genes are probably non-functional pseudogenes but in transfection experiments, 
DPαl and DPβ1 encode DP antigens and could function to present antigen to 
appropriate DP-restricted T cell clones (Kelly et al., 1985). 
Nomenclature of HLA alleles are updated as of July 2014 
(http://hla.alleles.org/)(Table 1.3) 
Table 1.3 :Nomenclature of HLA alleles(http://hla.alleles.org/) 
Nomenclature Indicates 
HLA the HLA gene region 
HLA-DPB1 a particular HLA locus DPB1 
HLA-DPB1*15 a group of alleles which encode the DP15 antigen or 
sequence homology to other DPB1*15 alleles 
HLA-DPB1*15:01 a specific HLA allele 
HLA-DPB1*15:01:02 an allele that differs by a synonymous mutation 
from DRB1*15:01:01 
HLA-DPB1*15:01:01:02 an allele which contains a mutation outside the coding 
region from DPB1*15:01:01:02 
 
Each HLA allele has a unique number and seperated by four sets of digits colons. 
First digits descripe the type (HLA) which related with serological antigen carried. 
The next set of digits are descriped to list the subtypes which DNA sequencing have 
been determined. If the allele numbers are different in two sets of digits, must be 
different at least one nucleotide substitutions. Alleles might be differ only by 
synonymous or non-coding substitutions that are distinguished by the use of the third 
set of digits. The fourth set digits are used that alleles only differ by sequence 
polimorphism both in the introns and in the 5’ or  3’ untranslated region (Table 1.3). 
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In addition to unique number of alleles, there are additional optional suffixes 
according to alleles expression status. If alleles have been shown that not to be 
expressed, suffix ‘N’ are described ‘Null’ alleles. These alleles may have the suffix 
‘L’, ‘S’ and ‘Q’ (http://hla.alleles.org/).The suffix ‘L’ is used to ‘Low’ cell surface 
expression of allele’s compared to normal levels. The ‘S’ suffix is used to denote an 
allele specifying a protein that is as  a soluble ‘secreted’ molecule but it is not present 
on the cell surface. The lastly ‘Q’ suffix is used to be expression of an allele 
‘questionable’ and affects normal levels (http://hla.alleles.org/). 
1.8 Genetic Association Studies 
Genetic association studies are used to find candidate genes or genome regions. Also 
these studies contribute a correlation between disease status and genetic variation for 
specific diseases. Associations with polymorphisms in candidate genes have been 
verified in many different diseases (Lewis C. et al., 2005). These studies are 
performed to determine whether a genetic variant is associated with a disease or trait: 
if association occurs, a particular allele, genotype or haplotype of a polymorphism 
may be shown more often than expected by chance in an individual. Hence, if a 
person carries one or two copies of a high-risk variant, he is at increased risk of 
developing the associated disease or having the associated trait. In association 
studies, SNPs are the most widely used test. Also, both genetic and environmental 
factors contribute to the susceptibility risk (Lewis C. et al.,2005). 
Candidate gene studies generally require multiple SNPs. Significant genetic 
association can be interpreted as 1- direct association, (the genotyped for the disease 
susceptibility); 2-indirect association, in linkage disequilibrium (LD);  3- a false-
positive result, (such as population stratification). Distinguishing between direct and 
indirect association may require the candidate region (Cathryn et al.,2012) (Lewis 
C.et al.,2005). 
In population genetics, Linkage disequilibrium (LD) is used in the study for the non-
random association of alleles at two or more loci. It may occur on the same 
chromosome or different chromosome than would be expected from a random 
formation of haplotypes from alleles based on their frequencies (Cathryn  et al.,2012) 
(Lewis C. et al.,2005). 
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Linkage Disequilibrium depends on three study groups:Case–Control Study,in 
genetic case-control studies, genotypes or the frequency of alleles are compared 
between the cases and controls. With the case-control design, genotype and 
haplotype frequencies can vary between ethnic or geographic populations (Cathryn et 
al.,2012). 
A difference in the frequency of an allele or genotype of the polymorphism may 
increase risk of the disease or be in linkage disequilibrium with a polymorphism. 
Haplotypes can also display association with a disease or trait. Family based 
association designs aim to avoid the potential confounding effects of population 
stratification. If an allele increases the risk of having a disease, in populations,that 
alleles can be transmitted from parent to offspring. A quantitative trait shows 
continuous variation, such as height or weight. Quantitative trait association can also 
be performed using an unrelated  population sample or family (Cathryn et al.,2012). 
Genome-wide association study (GWAS) using a inclusive approach for human 
genotyping showed single nucleotide polymorphisms (SNPs) that are located near 
HLA loci in chromosome 6p21 (Tamori et al., 2013;Hu et al., 2012). These are 
related with the outcomes of hepatitis virus infection (Mbarek et al., 2011). Many 
SNP candidates associated with common diseases were detected by GWAS (Nishida 
et al., 2012 Chan et al., 2011). According to previous studies, GWAS determined 
candidate SNPs of the HLA loci that are related with chronic HBV or HCV infection, 
hepatic fibrosis and hepatocellular carcinoma(Mbarek et al., 2011).  Moreover, 
recent GWAS done on chronic hepatitis B infected patients revealed SNPs in HLA 
class II genes, especially HLA-DPA1 and HLA-DPB1 region (Gebe et al., 2002; 
Tamori et al., 2013;Wong et al., 2013). 
Some studies show that genetic variants in the HLA-DP locus are effectively related 
with risk of persistent infection with hepatitis B virus (Gebe et al., 2002). In 
Japannese populations, HLA analysis demonstrated that HLA-DPA1*0202- 
DPB1*0501 and HLA- DPA1*0202-DPB1*0301 were risk types for persistent HBV 
infection, while HLA-DPA1*0103, DPB1*0402 and HLA-DPA1*0103,  
DPB1*0401 were protective alleles for HBV infection in Japanese population. 
Genome association analysis demonstrated that HLA loci are one of the most 
significant host determinants of the clinical characteristics of HBV and HCV 
infections (Wong et al., 2013; Kim et al., 2013). 
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Hardy Weinberg Equilibrium calculates the genotype frequencies from allele 
frequencies. This test supplies a comparison of the expected and observed genotype 
frequencies.For instance, for alleles G and T, the frequency of allele G is p and the 
frequency of allele T is q = (1 – p), the expected frequencies of genotypes GG, GT, 
and TT are p2, 2pq, and q2 (Cathryn et al.,2012). 
1.9 Hypothesis 
Recent genetic association studiesrevealed that HBV infection related diseases are 
associated with the variations observed in the HLA-DP region of the genome. Our 
study investigates the presence of possible variations in the HLA-DP region in 
Turkish population that were infected by HBV. We think that our study could 
determine alterations in the HLA-DPB1 site of the genome of HBV infected Turkish 
patients and link these possible polymorphisms to disease outcome in Turkish 
population. 
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2. MATERIAL AND METHODS 
2.1. Materials and Laboratory Equipments 
2.1.1 Used equipments 
The laboratory equipment used for this project was listed in Appendix A. 
2.1.2 Used chemicals, enzymes, markers and buffers 
The chemicals, markers and enzymes used were given in Appendix B together with 
their suppliers.The preparation and compositions of buffers and solutions were 
shown in Appendix C. 
2.2 Selection criteria of the chronic hepatitis B patients and control group 
A total of 94 unrelated Turkish subjects were used in this study, from Department of 
Gastroenterology, Goztepe Teaching and Research Hospital. A case group of 
asymptomatic HBV carriers were recruited according to the results of serological 
tests (liver functional indexes, HBV virological indexes) and symptoms of hepatitis 
B. Chronic hepatitis B was diagnosed if serum levels of alanine aminotransferase 
(ALT) and aspartate aminotransferase (AST) were continuously abnormal, with 
HBsAg and/or HBeAg seropositive, anti-HBs antibodies (anti-HBs) seronegative. 
Asymptomatic HBV carriers wereidentified with the following diagnostic criteria: 
HBsAg seropositive last for more than 1 year, with normal liver functional indexes 
and without any signs and symptoms of hepatitis and HBV DNA levels were below 
2000 IU. 
The control group was selected from the healthy people of the Goztepe Teaching and 
Research Hospital. The ages of the controls change between 38 and 49. The members 
of the control group have no known history of any chronic inflammatory diseases, 
free from acute or chronic hepatitis B virus infection at the time of the study and 
their functional capacity was sufficient. 
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2.3 Collection and Storage of Blood Samples 
The peripheral blood samples were collected from the patients of Department of 
Gastroenterology, Goztepe Teaching and Research Hospital and chosen as respect to 
the chronic hepatitis B criteria defined previously. The blood samples were collected 
in vacuum tubes with EDTA. The samples were stored at −80 C. 
2.4 DNA Isolation from Human Whole Blood 
Genomic DNA (gDNA) isolation was done by using Invıtrogen PureLink Genomic 
DNA Purification Kit (Invitrogen). For each isolation process approximately 1 mL of 
peripheral blood sample was used. The isolated stock DNA was stored at -20 °C.  
2.5 DNA Amount, Purity and Working Solution Calculations 
The concentration and purity of the isolated DNA was calculated based on the 
absorbance values measured at 260, 280 and 320 nm. of the spectrometer. The 
concentration of the DNA was calculated by equation 2.1 and the purity of the DNA 
samples were calculated by equation 2.2 given below.  
DNA Concentration (ng / L) (A260- A320 )X 50X Dilution Factor 2.1  
DNA Purity= A260-A320/ A280-A320 2.2  
In order to have a set of DNA samples containing same amount of DNA (50 ng/μL), 
dilutions from the stock DNA were prepared (working solutions). The required 
amount of stock DNA solutions was calculated for 500 μL of 50 ng/μL working 
solutions (approximately 25 μg DNA).  
2.6 Polymerase Chain Reaction (PCR) Amplification 
Isolated genomic DNAs of the chronic hepatitis B group were used for PCR reaction. 
Primers sequences and PCR product sizes are listed in Table 2.1. 
2.6.1 Oligonucleotid primers 
The oligonucleotide primers used in this study are given in the Table 2.1 below. The 
confirmation of the actually binding sites, binding efficiencies and amplicon sizes 
was made by Amplify 3X software.  
As it was also essential to analyze the primer sets for dimer formation, the hairpin, 
heterodimer and self dimer analysis of the primer set were done and confirmed with 
the SciTools on the IDT DNA website (OligoAnalyzer 3.0). PCR Product size 299 
bp. 
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Table 2.1 : List of primersused in the study 
Gene Sequencing (5’ to 3’) PCR 
Product 
 
 
DPB1 
primers 
 
 
 
5’primer 
 
 
GTGAAGCTTTCCCCGCAGAGAATTAC 
 
 
 
 
 
299 
 
3’primer 
 
ACCTGCAGTCACTCACCTCGGCGCTG 
 
2.6.2 PCR conditions 
The PCR cycle conditions are varied according to the desired amplicon. In this study, 
PCR cycle conditions are given in the Table 2.2 below. 
Table  2.2: PCR  conditions 
1 X 1 X  
DNA 2.5 µl 
10XGreen Buffer 5 µl 
MgCl2 2 µl 
dNTP 4 µl 
F-Primer 1 µl 
R-Primer 1 µl 
TagPolymerase 0.25 µl 
dH2O 34.25 µl 
Total reaction 50 µl 
 
2.6.3 PCR optimization 
Generally, PCR reactions were required optimization for higher performance related 
with the amplification of the correct target and determination of appropriate 
annealing temperature for primer set. In this thesis, PCR conditions were optimized 
via gradient PCR methods. 
2.6.4 Gradient PCR 
It is necessary to use gradient PCR to determine the optimum annealing temperature 
for a PCR reaction when appropriate annealing temperature is not known for a 
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primer set. In gradient PCR, the thermo cycler is set in such a way that the wells in 
the thermo cycler block have a gradient of temperature from high to low for the 
annealing phase of the cycles.Hence, gradient PCR allows the run of a set of 
identical PCR in the same block with different annealing temperatures, which saves 
time and prevents multiple usage of the thermo cycler for the same optimization. 
After analyzing the PCR products with agarose gel electrophoresis, annealing 
temperature of the PCR mixture giving the best band intensity waschosen as the 
optimum annealing temperature. In this thesis, the optimization of the annealing 
temperature of PCR was made by gradient PCR by forming a gradient from 58 to 
65°C and the best band intensity was seen at 60°C, therefore this temperature was 
used as the annealing temperature of HLA alleles PCR for the rest of the studies. 
2.6.5 PCR cycle conditions of HLA DPB1alleles 
The PCR conditions for the HLA DPB1gene region is shown in the Table 2.3 
Table 2.3 :PCR cycle conditions for the HLA DPB1gene region 
Repeat Number 
Degree 
 
Time 
Phase 
 
1 94 °C 3 minute Initial denaturation 
 
38 
94 °C 30 seconds Denaturation 
60°C 30 seconds Annealing 
72°C 50 second Extension 
1 72°C 7 minute Final Extension 
2.6.6 Agarose gel electrophoresis of PCR products 
The right percentage of an agarose gel is beneficial for observing the PCR bands 
accurately. In this thesis, the PCR products of amplicon sizes can be seen on a 2% 
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agarose gel. PCR products is observed either on 2% mini gels prepared with 2.0 g 
agarose into 100 mL and maxi gels prepared with 2.4g agarose into 120 mL of 1X 
TAE buffer, which is diluted from 50X stock TAE. 5 μL of PCR product is mixed 
with 1 μL SyberGreen in order to load into the wells. Lengths of the PCR products 
are calculated according to O‟RangeGeneRuler Low Range marker (Fermentas) and 
O‟RangeGeneRuler Ultra Low Range marker (Fermentas). The gels are run in 1X 
TAE buffer, at 100V with power supplier, for at least 30 minutes. The observations 
of the gels under UV light are made by transilluminator and UV PhotoMW software 
is used in order to take the photos of the gels. 
2.7 PCR-RFLP (Restriction Fragment Length Polymorphism) Method 
The study depends on PCR-RFLP method using some restriction enzymes which 
have either a single cleavage site or, alternatively no cleavage site in the amplified 
DNA region, based on the HLA alleles, making reading of RFLP band patterns much 
easier. 9 different restriction endonucleases, Bsp12861, FokI, DdeI, BsaJI, BssHII, 
Cfrl31, RsaI, EcoNI and AvaII, were selected for digestion to detect allele- specific 
cleavage after PCR-amplification of the DPBl alleles. Fragments (bp) detected by 
digestion of the PCR-amplified DPBl genes by 9 different restriction endonucleases 
DPB1 alleles are shown in the Table 2.5 below and after the PCR amplification 
RFLP reaction are given in the Table 2.6 below. 
Table 2.4: Reaction Conditions of Restriction Endonucleases 
 
Restriction 
Endonucleases 
Degree Incubation 
Time 
Inactivation 
Degree 
Inactivation 
Time 
Bsp1286I 
37°C 
10h 
60°C 20m 
FokI 1h 
AvaII 
37°C 10h 
DdeI 
BssHII 
Cfr13I 
RsaI 
EcoNI 
BsaJI 55°C 10h 80°C 20m 
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Table 2.5: After the PCR amplification, RFLP reaction 
 
 
 
 
 
2.8 Agarose Gel Electrophoresis of RFLP Analyzes 
In this study, the RFLP analyzes after the PCR amplification can be seen on a  
different percentage of agarose in the agarose gel. RFLP analyzes is observed either 
on 2% mini gels prepared with 2.0g agarose into 100 mL of 1X TAE buffer, which is 
diluted from 50X stock TAE. 10 μL of PCR product is mixed with 1 μL 6X loading 
dye and with 1 μL SyberGreen in order to load into the wells.Differentpercentage of 
agoroseaccording to restriction endonucleases were given in theTable 2.8. Lengths of 
the RFLP Products were calculated according to O‟Range GeneRuler LowRange 
marker (Fermentas) and O‟Range GeneRuler Ultra Low Range marker (Fermentas). 
The gels were run in 1X TAE buffer, at 90V with power supplier, for at least 40 
minutes. The observations of the gels under UV light were made bytransilluminator 
and UV PhotoMW software was used to take the photos of the gels. 
Table 2.6 :DifferentPercentage of AgoroseGel according to Restriction 
Endonucleases 
 
2.9 Genotyping 
The genotyping was done by analyzing the agarose gel photos of  PCR-RFLP 
products for the all HLA DPB1 alleles observed in patients, respectively. O‟Range 
GeneRuler LowRange (Fermentas) or O‟Range GeneRuler Ultra LowRange 
(Fermentas) markers were also loaded to decide the band sizes along with positive 
Add Amount of  1X 
PCR Product 12µl 
Nuclease Free Water 6 µl 
10X Buffer 2 µl 
Enzymes 0.4µl 
Total 20µl 
Restriction 
Enzymes 
Bsp1286I FokI DdeI BsaJI BssHII Cfr13I RsaI EcoNI AvaII 
% Agarose Gel %2 %2 %2 %4 %2 %2 %4 %4 %2 
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controls. Indeed, the allelic type was determined according to the presence or 
absence of the desired length PCR products. 
2.10 Statistical Analysis 
In this study, to analyze the association of HLA DPB1 alleles in patients with chronic 
hepatitis B infection, statistical analyses were performed. A 2 × 2 contingency table 
was used to compare allelic frequencies according to clinical statues of the patients. 
All statistical analyses were performed using the SPSS program, version 21 (SPSS, 
Chiacago, IL). Analysis of categorical data and HLA alleles, where 2 × 2 
contingency table was used, statistically were performed by χ2 test. In case of 
expecting any data bellow  in any cell in 2 × 2 contingency table, Fisher’s exact test 
was used. Additionally, we used Hard Weinberg analysis using HWE calculator. In 
all analysisone-sided p was taken into account and if p<0.05 it was considered as 
significant. 
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3. RESULTS 
3.1 Demographic Data of the Chronic Hepatitis B Group 
In this study, a total of 94 hepatitis B patients (group A) were included from 
Department of Gastroenterology, Hepatology Clinic, Goztepe Teaching and 
Research Hospital.Age and gender matched 85 HBsAg negative, anti-HBs positive 
and anti–HBc IgG positive spontaneous seroconverted healthy subjects (group B) 
were also included in the study. 
Group A, the patient group,consists of 58 male (61.7%) and 36 (38.3%) female 
patients with a  mean age 47.9±14.7.  Among these patients 71 (75%) of them were 
HBeAg negative, 16 (17%) had inactive disease. The pretreatment mean ALT,AST 
and log DNA were 102.1±113 U/L, 70±96 U/L and 4.9±2.8 IU/ml, respectively. 
Among them 54 (57.4%) had liver biopsy; the mean Ishak fibrosis score was 2±1.5 
and hepatic activity index was 6.5±3.3. Twenty (21.3%) patients had cirrhosis. 
Table 3.1: Demographic data of the sample population 
Patient Group (Group A) n (%) 
Sex Male 58 (61.7)  
Female 36 (38.3)  
HBeAg Negative 23 (25) 
Positive 71 (75)  
Cirrhosis yes 20 (21.3)  
no 74 (78.7) 
Control  Group (Group B) n (%) 
Sex Male 46 (54,1) 
Female 39 (45,9) 
HBsAg Negative 85 (100) 
Positive 0 (0) 
Anti HBsAg Negative 0 (0) 
Positive 85 (100) 
Anti HBc IgG Negative 0 (0) 
Positive 85 (100) 
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The mean follow up time for the patients was 76±52 months. 
Control group was constructed (Group B) from healthy people who had already 
hepatitis B infection with spontaneous HBsAg seroconversion (HBsAg negative, 
Anti HBs positive, Anti HBc IgG positive). Group B has 54% male, 46% female 
individuals and the age average of this group was 54±13 (Table 3.1). 
We also used historical controls as Group C by taking disease related information 
directly from the published literature, which includes Turkish and German 
populations. Group C is used to compare HLA-DPB1 frequencies from general 
population with the disease population of this study.  
3.2 DNA Isolation Results 
In this thesis, DNA isolation was done according to the procedure provided by 
Invitrogen PureLink Genomic DNA Purification Kit.  
3.3 Genotype Analysis 
3.3.1 PCR results 
In this study, we did PCR reactions to amplify the target HLA DPB1 DNA sequence. 
Selected primers (Table 3.2) are used in the PCR reaction, and the resulting PCR 
product has a mass corresponding to 299 bp (Ota et al., 1991). 
Table 3.2 : Selected primers from the HLA-DPB1 gene region 
GGGTGGGAAGATTTGGGAAGAATCGTTAATATTGAGAGAGAGAGGGAGAAAGAGGATTAGATGAGAGTGGCGCCTCCGCTCATGT
CCGCCCCCTCCCCGCAGAGAATTACCTTTTCCAGGGACGGCAGGAATGCTACGCGTTTAATGGGACACAGCGCTTCCTGGAGAGA
TACATCTACAACCGGGAGGAGTTCGCGCGCTTCGACAGCGACGTGGGGGAGTTCCGGGCGGTGACGGAGCTGGGGCGGCCTGCTG
CGGAGTACTGGAACAGCCAGAAGGACATCCTGGAGGAGAAGCGGGCAGTGCCGGACAGGATGTGCAGACACAACTACGAGCTGGG
CGGGCCCATGACCCTGCAGCGCCGAGGTGAGTGAGGGCTTTGGGCCGGCGGTCCCAGGGCAGCCCCGCGGGCCCGTGCCCAGGGC
GCAGGAGCAGCCGGGTTGGCCTAAGGGACCTTAGTGCCGGGCGGAAAGGGGACTTTGGGTTGGGGATTCATGGGGGGAGCCCATC
TGGAGCTTGTCAGGGGAGCGAGCGCG 
 
The genotyping was done by comparing the bands on the agarose gel. An example of 
a PCR gel isshown in Figure 3.1. 
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Figure 3.1 :Agarose gel electrophoresis analysis on 2.0% agarose gel for the target DNA 
sequences, HLA-DPB1gene, from blood samples. Lanes: M, size marker DNA (100-bp DNA ladder), 
from patient groups, 51–57 lines show each number of amplified PCR reaction. The number on the 
left indicates the molecular size (in base pairs) of the amplified PCR products which are 299 bp. 
3.3.2 PCR-RFLP results 
Our study is based on a PCR-RFLP method using restriction enzymes to genotype 
HLA-DPB1 alleles from HBV infected patients and HBV infected healthy subjects. 
These restriction endonucleases have shown us that homozygotes and heterozygotes 
can be unequivocally discriminated in the amplified DNA region. DPB1 gene was 
selectively amplified from genomic DNAs of 94patients and 85 healthy Turkish 
people by PCR. Amplified DNAs were digested with restriction endonucleasesand 
then subjected to electrophoresis, assaying simply forcutting, or no cutting, of the 
DNAalleles of the DPBl gene. After the PCR amplification, 9 restriction enzymatic 
cut patterns were analyzed on agarose gel electrophoresis. These restriction 
endonucleases are Bsp12861, FokI, DdeI, BsaJI, BssHII, Cfrl31, RsaI, EcoNI, and 
AvaII enzymes (Ota et al., 1991). 
This modified PCR-RFLP method can be successfully applied to heterozygotes (Ota 
et al., 1991). Examples of the PCR-RFLP results are shown in Figures3.2, 3.3, 3.4, 
3.5, 3.6, 3.7, 3.8, 3.9, 3.10. The rest of the PCR-RFLP results are shown in Appendix 
D. 
Patient  numbers 
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In this study, 299 base pair non-cleaved fragments were indicated as "0" and cleaved 
fragments were marked  as "1", showing these alleles as homozygotes. If the number 
consists of both celaved and non-cleaved fragments, this suggests the presence of 
heterozygotes as "0/1". 
Each restiriction enzyme cleavage results is shown seperately: 
3.3.2.1 FokI restriction enzyme 
19alleles of the DPBl gene can be discriminated with 9 different restriction enzymes. 
Table 3.3 shows the cleavage fragments of FokI restriction enzyme with 19 DPB1 
alleles depending on the base pairs after the agarose gel electrophoresis.  
Table 3.3 :Fragments (bp) detected by digestion of the PCR-amplified DPBl genes 
by FokI restriction endonuclease 
 
FokI restriction endonuclease’s recognition sites are indicated  as below: 
5'...G G A T G (N)9↓...3' 
3'...C C T A C (N)13↑...5' 
 
Our RFLP experiments are shown in Figure 3.2 for the FokI restriction enzyme. This 
is a representative figure for the digest experiment. In Figure 3.2, the presence of 
heterozygotes are shown in lanes corresponding to 81, 83 and 84 due to the presence 
of both cleaved fragments and the uncleaved form of the PCR product. The rest of 
the lanes have cleavage patterns suggesting the presence of only homozygotes 
(Figure 3.2). The number on the left indicates the molecular size (in base pairs) of the 
amplified PCR products. The number on the right indicates the molecular size (in 
base pairs) of FokI enzyme’s cleavage patterns.  
DPB1 Alleles
0401 0402 0201 1801 0202 0801 0501 0301 0601 1101
Fokl 186 57 56 183 59 57 183 59 57 183 59 57 183 59 57 183 116 183 59 57 299 242 57 242 57
0101 0901 1001 1301 1901 1401 1501 1601 1701
Fokl 183 116 183 116 183 116 183 116 183 116 299 242 57 183 59 57 183 59 57
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Figure 3.2:Agarose gel electrophoresis analysis on 2.0% agarose gel of RFLP-PCR methods  from 
blood samples. Lanes: M, size marker DNA (100 bp DNA ladder); from patient groups, 81–87 lines 
show each number of amplified by Fok I restriction enzyme ). Cleaved fragments were marked  as 
"1", showing these alleles as homozygotes. If the number consists of both celaved and non-cleaved 
fragments, this suggests the presence of heterozygotes as "0/1". 
 
3.3.2.2 AvaII restriction enzyme 
Cleavage sites depending on the base pairs after the agarose gel electrophoresis for 
AvaII restriction endonuclease are shown in Table 3.4 with 19 HLA-DPB1 alleles. 
Table 3.4:Fragments (bp) detected by digestion of the PCR-amplified DPBl genes 
byAvaII restriction endonuclease 
 
AvaII restriction endonuclease’s recognition sites are indicated  as below: 
5'...G↓G W C C...3' 
3'...C C W G↑G...5' 
 
Our RFLP experiments are shown in Figure 3.3 for the AvaII restriction enzyme. In 
Figure 3.2  the presence of heterozygote is shown in lane corresponding to 91 due to 
the presence of both cleaved fragments and the uncleaved form of the PCR product. 
DPB1 Alleles
0401 0402 0201 1801 0202 0801 0501 0301 0601 1101
Avall 299 299 299 299 299 299 299 194 105 194 105 194 105
0101 0901 1001 1301 1901 1401 1501 1601 1701
Avall 299 299 299 299 299 194 105 194 105 299 299
0/1         1          0/1      0/1   1         1 1 1 
 
188bp 
111bp 
 
 
Patient numbers 
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The rest of the lanes have cleavage patterns suggesting the presence of only 
homozygotes (Figure 3.3). The number on the left indicates the molecular size (in 
base pairs) of the amplified PCR products. The number on the right indicates the 
molecular size (in base pairs) of AvaII enzyme’s cleavage patterns. 
 
 
Figure 3.3: Agarose gel electrophoresis analysis on 2.0% agarose gel of RFLP-PCR methods  from 
blood samples. Lanes: M, size marker DNA (100 bp DNA ladder); from patient groups, 86–91 lines 
show each number of amplified by Ava II restriction enzyme. 299 base pair non-cleaved fragments 
were indicated as "0, showing these alleles as homozygotes. If the number consists of both celaved 
and non-cleaved fragments, this suggests the presence of heterozygotes as "0/1". 
3.3.2.3 BsaJI restriction enzyme 
Table 3.5 shows the cleavage fragments of BsaJI restriction enzyme with 19 HLA-
DPB1 alleles after the agarose gel electrophoresis.  
Table 3.5 :Fragments (bp) detected by digestion of the PCR-amplified DPBl genes 
by BsaJI restriction endonuclease 
 
BsaJ restriction endonuclease’s recognition sites are indicated  as below: 
5'...C↓C N N G G...3' 
3'...G G N N C↑C...5' 
 
DPB1 Alleles
0401 0402 0201 1801 0202 0801 0501 0301 0601 1101
BsaJl 246 32 21 246 32 21 246 32 21 246 32 21 246 32 21 246 32 21 246 32 21 278 21 278 21 278 21
0101 0901 1001 1301 1901 1401 1501 1601 1701
BsaJl 246 32 21 278 21 278 21 278 21 246 32 21 278 21 246 32 21 246 32 21 278 21
    0           0          0           0        0/1        
 1 1
 1 
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Our RFLP experiments are shown in Figure 3.4 for the BsaJI restriction enzyme. 
This is a representative figure for the digest experiment. In Figure 3.4, the presence 
of heterozygotes are shown in lanes corresponding to 145, 146 and 147 due to the 
presence of  both cleaved fragments and the uncleaved form of the PCR product. The 
rest of the lanes have cleavage patterns suggesting the presence of  homozygotes 
(Figure 3.2). The number on the left indicates the molecular size (in base pairs) of the 
amplified PCR products. The number on the right indicates the molecular size (in 
base pairs) of BsaJI enzyme’s cleavage patterns. 
 
 
Figure 3.4: Agarose gel electrophoresis analysis on 4.0% agarose gel of RFLP-PCR methods  from 
blood samples. Lanes: N, Negative control;from control groups, 142–147 lines show each number of 
amplified by BsaJI restriction enzyme.Cleaved fragments were marked  as "1", showing these alleles 
as homozygotes. If the number consists of both celaved and non-cleaved fragments, this suggests the 
presence of heterozygotes as "0/1". 
3.3.2.4 Cfr13I restriction enzyme 
Cleavage sites depending on the base pairs after the agarose gel electrophoresis for 
Cfr13I restriction endonuclease are shown in Table 3.6 with 19 HLA-DPB1 alleles.  
Table 3.6 :Fragments (bp) detected by digestion of the PCR-amplified DPBl genes 
by Cfr13I restriction endonuclease 
 
DPB1 Alleles
0401 0402 0201 1801 0202 0801 0501 0301 0601 1101
Cfr13l 258 40 258 40 258 40 258 40 258 40 299 299 194 105 194 105 194 105
0101 0901 1001 1301 1901 1401 1501 1601 1701
Cfr13l 299 299 299 299 299 194 105 194 64 40 299 299
1      1      1     0/1    0/1   0/1 Numerical representation 
of  allelic distribution 
Controlgroup numbers 
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BsaJ restriction endonuclease’s recognition sites are indicated  as below: 
5'...G↓G N C C...3' 
3'...C C N G↑G...5' 
 
Our RFLP experiments are shown in Figure 3.5 for the Cfr13I restriction enzyme. 
This is a representative figure for the digest experiment. In Figure 3.5, the presence 
of heterozygotes are shown in lanes corresponding to 143, 144, 36 and 64 due to the 
presence of both cleaved fragments and the uncleaved form of the PCR product. In 
lane 142 has cleavage patterns suggesting the presence of only homozygote (Figure 
3.5). The number on the left indicates the molecular size (in base pairs) of the 
amplified PCR products. The number on the rightindicates the molecular size (in 
base pairs) of Cfr13I enzyme’s cleavage patterns. 
 
Figure 3.5:Agarose gel electrophoresis analysis on 2.0% agarose gel of RFLP-PCR methods  from 
blood samples. Lanes N, Negative control;from control groups, 142–64 lines show each number of 
amplified by Cfr13I restriction enzyme. Cleaved fragments were marked  as "1", showing these alleles 
as homozygotes. If the number consists of both celaved and non-cleaved fragments, this suggests the 
presence of heterozygotes as "0/1". 
3.3.2.5 Bsp1286I restriction enzyme 
Table 3.7 shows the cleavage fragments of Bsp1286I restriction enzyme with 19 
HLA-DPB1 alleles after the agarose gel electrophoresis. 
 
 
1        0/1      0/1      0/1       0/1 Numerical representation 
of  allelic distribution 
Controlgroup numbers 
35 
 
Table 3.7:Fragments (bp) detected by digestion of the PCR-amplified DPBl genes 
by  Bsp1286I restriction endonuclease 
 
Bsp1286I restriction endonuclease’s recognition sites are indicated  as below: 
5'...G D G C H↓C...3' 
3'...C↑H C G D G...5' 
 
Our RFLP experiments are shown in Figure 3.6 for the Bsp1286I restriction enzyme. 
It can be observed from the figure that  in lanes 27,28 and 29, there are no digestions 
as observed from the single band. Only the last lane 36, there is a digestion pattern 
suggesting the presence of homozygote. The number on the left indicates the 
molecular size (in base pairs) of the amplified PCR products. The number on the 
rightshows the molecular size (in base pairs) of Bsp1286I enzyme’s cleavage 
patterns. 
 
 
Figure 3.6 :Agarose gel electrophoresis analysis on 2.0% agarose gel of RFLP-PCR methods  from 
blood samples. Lanes: M, size marker DNA (100 bp DNA ladder); N, Negative control ;from control 
groups, 27–36 lines show each number of amplified by Bsp1286I  restriction enzyme.299 base pair  
non-cleaved fragments were indicated as "0" and cleaved fragments were marked  as "1", showing 
these alleles as homozygotes. 
DPB1 Alleles
0401 0402 0201 1801 0202 0801 0501 0301 0601 1101
Bspl2861 262 37 262 37 262,37 262 37 153 109 37 299 190 109 299 299 299
0101 0901 1001 1301 1901 1401 1501 1601 1701
Bspl2861 299 268 31 268 31 299 299 268 31 262 37 299 268 31
0        0      0         1 Numerical representation 
of  allelic distribution 
Control group numbers 
36 
 
3.3.2.6 DdeI restriction enzyme 
Cleavage sites depending on the base pairs after the agarose gel electrophoresis for 
DdeI restriction endonuclease with 19 HLA-DPB1 alleles are shown in Table 3.8 
Table 3.8:Fragments (bp) detected by digestion of the PCR-amplified DPBl genes 
by DdeI restriction endonuclease 
 
DdeI restriction endonuclease’s recognition sites are indicated  as below: 
5'...C↓T N A G...3' 
3'...G A N T↑C...5' 
 
Our RFLP experiments are shown in Figure 3.7 for the DdeI restriction enzyme. In 
Figure 3.7, the presence of heterozygote is shown in lane corresponding to 143 due 
to the presence of both cleaved fragments and the uncleaved form of the PCR 
product. It can be observed from the figure that in lanes 138 and the rest until 143, 
there are no digestions as observed from the single band suggesting the presence of 
only homozygotes (Figure 3.7) The number on the left shows the molecular size (in 
base pairs) of the amplified PCR products. The number on the rightindicates the 
molecular size (in base pairs) of Ddel enzyme’s cleavage patterns. In general all our 
patients revealed non-digestion patterns for the DdeI restriction enyme. 
 
 
DPB1 Alleles
0401 0402 0201 1801 0202 0801 0501 0301 0601 1101
Ddel 299 299 299 299 166 133 299 166 133 299 299 299
0101 0901 1001 1301 1901 1401 1501 1601 1701
Ddel 299 299 299 299 166 133 299 299 299 299
0        0       0       0       0        0/1 
 
Numerical representation 
of  allelic distribution 
Patient numbers 
37 
 
Figure 3.7 :Agarose gel electrophoresis analysis on 2.0% agarose gel of RFLP-PCR methods  from 
blood samples. Lanes N, Negative control;from control groups, 138–143 lines show each number of 
amplified by Ddel  restriction enzyme.299 base pair  non-cleaved fragments were indicated as "0", 
showing these alleles as homozygotes. If the number consists of both celaved and non-cleaved 
fragments, this suggests the presence of heterozygotes as "0/1". 
3.3.2.7 BssHII restriction enzyme 
The cleavage fragments of BssHII restriction enzyme with 19 HLA-DPB1 alleles are 
shown in Table 3.9Cleavage sites depending on the base pairs after the agarose gel 
electrophoresis. 
Table 3.9 :Fragments (bp) detected by digestion of the PCR-amplified DPBl genes 
byBssHII restriction endonuclease 
 
BssHII restriction endonuclease’s recognition sites are indicated  as below: 
5'...G↓C G C G C...3' 
3'...C G C G C↑G...5' 
 
Our RFLP experiments are shown in Figure 3.8 for the BsHII restriction enzyme. 
This is a representative figure for the digest experiment and this figure could observe 
that in lanes 123 and 124, there are no digestions as observed from the single 
bandsuggesting the presence of only homozygotes. In Figure 3.8 the presence of 
heterozygotes are shown in lanes corresponding to 121, 125, 126, 127 and 128 due to 
the presence of both cleaved  fragments and the uncleaved form of the PCR product. 
The number on the left shows the molecular size (in base pairs) of the amplified PCR 
products. The number on the right indicates the molecular size (in base pairs) of 
BssHll enzyme’s cleavage patterns. 
DPB1 Alleles
0401 0402 0201 1801 0202 0801 0501 0301 0601 1101
BssHll 188 111 299 299 299 299 299 299 299 299 181 111
0101 0901 1001 1301 1901 1401 1501 1601 1701
BssHll 181 111 299 299 181 111 299 299 181 111 299 299
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Figure 3.8 :Agarose gel electrophoresis analysis on 2.0% agarose gel of RFLP-PCR methods  from 
blood samples. Lanes: N, Negative control;from control groups, 122–128 lines show each number of 
amplified by BssHll restriction enzyme.Cleaved fragments were marked  as "1", showing these alleles 
as homozygotes. If the number consists of both celaved and non-cleaved fragments, this suggests the 
presence of heterozygotes as "0/1". 
3.3.2.8 RsaI restriction enzyme 
Cleavage sites depending on the base pairs after the agarose gel electrophoresis for 
RsaI restriction endonuclease are shown in Table 3.10 
Table 3.10: Fragments (bp) detected by digestion of the PCR-amplified DPBl genes 
byRsaI restriction endonuclease 
 
RsaI restriction endonuclease’s recognition sites are indicated  as below: 
5'...G T↓A C...3' 
3'...C A↑T G...5' 
 
Our RFLP experiments are shown in Figure 3.9 for the RsaI restriction enzyme. This 
is a representative figure for the digest experiment. In Figure 3.9, the presence of 
heterozygotes are shown in lanes corresponding to 35, 53, 81, 82 and 83 due to the 
presence of both cleaved fragments and the uncleaved form of the PCR product. The 
rest of the lanes have cleavage patterns suggesting the presence of only homozygotes 
(Figure 3.9). The number on the left indicates the molecular size (in base pairs) of the 
DPB1 Alleles
0401 0402 0201 1801 0202 0801 0501 0301 0601 1101
Rsal 177 122 177 122 177 122 147 122 30 177 122 177 122 177 122 269 30 269 30 147 122 30
0101 0901 1001 1301 1901 1401 1501 1601 1701
Rsal 122 78 69 30 299 177 122 122 78 69 30 177 122 299 122 78 69 30 177 122 299
0/1      0      0         0/1    0/1   0/1    0/1 Numerical representation 
of  allelic distribution 
Patient numbers 
39 
 
amplified PCR products. The number on the right shows the molecular size (in base 
pairs) of Rsal  enzyme’s cleavage patterns. 
 
 
Figure 3.9 :Agarose gel electrophoresis analysis on 4.0% agarose gel of RFLP-PCR methods  from 
blood samples. Lanes: M, size marker DNA (100 bp DNA ladder); N, Negative control;from control 
groups, 26–86 lines show each number of amplified by RsaI restriction enzyme.Cleaved fragments 
were marked  as "1", showing these alleles as homozygotes. If the number consists of both celaved 
and non-cleaved fragments, this suggests the presence of heterozygotes as "0/1". 
3.3.2.8 EcoNI restriction enzyme 
Table 3.11 shows the cleavage fragments of RsaI restriction enzyme with 19 HLA-
DPB1 alleles after the agarose gel electrophoresis. 
Table 3.11:Fragments (bp) detected by digestion of the PCR-amplified DPBl genes 
by EcoNI restriction endonuclease. 
 
RsaI restriction endonuclease’s recognition sites are indicated  as below: 
5'...C C T N N↓N N N A G G...3' 
3'...G G A N N N↑N N T C C...5' 
 
Our RFLP experiments are shown in Figure 3.10 for the EcoNI restriction enzyme. 
This is a representative figure for the digest experiment. In Figure 3.10, the presence 
of heterozygotes are shown in lanes corresponding to 99, 100, 103 and 106 due to the  
DPB1 Alleles
0401 0402 0201 1801 0202 0801 0501 0301 0601 1101
EcoNl 269 30 269 30 174 95 30 299 174 95 30 174 95 30 269 30 201 98 201 95 30 201 98
0101 0901 1001 1301 1901 1401 1501 1601 1701
EcoNl 299 204 95 204 95 201 98 174 95 30 201 98 201 98 174 95 30 204 95
1   0/1   0/1  0/1 0/1   0/1  1 Numerical representation 
of  allelic distribution 
Patient numbers 
40 
 
presence of both cleaved fragments and the uncleaved form of the PCR product. In 
lanes 98, 101, 104 and 105, there are no digestion as observed from the single band 
suggesting the presence of only homozygotes (Figure 3.10). The number on the left 
shows the molecular size (in base pairs) of the amplified PCR products. The number 
on the right indicates the molecular size (in base pairs) of EcoNI enzyme’s cleavage 
patterns. 
 
 
Figure 3.10 :Agarose gel electrophoresis analysis on 4.0% agarose gel of RFLP-PCR methods  
from blood samples. Lanes: M, size marker DNA (50 bp DNA ladder); N, Negative control;from 
patient groups, 98–106 lines show each number of amplified by EcoNl  restriction enzyme.299 base 
pair  non-cleaved fragments were indicated as "0", showing these alleles as homozygotes. If the 
number consists of both celaved and non-cleaved fragments, this suggests the presence of 
heterozygotes as "0/1". 
To detect which alleles patients have, Table 3.12 is used as a matrix. Since, 299 base 
pair non-cleaved fragments were indicated as "0" and cleaved fragments were 
marked as "1" in Table 3.12. The total restriction cleavage results compile to 
generate the allelic frequencies of the patients and controls. 
 
 
 
 
 0  -   0/1  0/1  0     0/1    0    0     0/1 Numerical representation 
of  allelic distribution 
Patient numbers 
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Table 3.12: Correlation between cleavage patterns obtained by 9 restriction 
endonucleases and DPB1 alleles (Ota et al., 1991) 
 Restriction Endonucleases 
DPB1 Allele Group Bspl2861 Fokl Ddel BsaJl BssHll Cfr13l Rsal EcoNl Avall 
0401 A 1 1 0 1 1 1 1 0 0 
1801=0402* B 1 1 0 1 0 1 1 0 0 
0201 C 1 1 0 1 0 1 1 1 0 
0202 D 1 1 1 1 0 1 1 1 0 
0801=1601* E 0 1 0 1 0 0 1 1 0 
0501 F 1 1 1 1 0 0 1 0 0 
0301 G 0 0 0 0 0 1 1 1 1 
0601 H 0 1 0 0 0 1 1 1 1 
1101 I 0 1 0 0 1 1 1 1 1 
0101 J 0 1 0 1 1 0 1 0 0 
0901=1701* K 1 1 0 0 0 0 0 1 0 
1001 L 1 1 0 0 0 0 1 1 0 
1301 M 0 1 0 0 1 0 1 1 0 
1901 N 0 1 1 1 0 0 1 1 0 
1401 O 1 0 0 0 0 1 0 1 1 
1501 P 1 1 0 1 1 1 1 1 1 
0: not cleaved, 1: cleaved 
*: DPB1*1801= 0402 can be discriminated after digestion with Rsal. A 147bp fragment is positive for 
DPB1*1801, while a l77bp fragment positive for DPB1*0402 and heterozygote DPB1*1801/0402 has 
both 147 and 177 bp fragments. DPB1*0801 and 1601 can be discriminated by detecting RFLP bands 
digested with  Fokl (116bp positive for 0801 and 59bp positive for 1601). DPB1*0901 and 1701 can 
be discriminated by detecting RFLP bands after digestion with Fokl (116bp positive for 0901 and 
59bp positive for 1701) (Ota et al., 1991). 
3.4 HLA Results 
Among the 19 analyzed DPB1 alleles in this study, DPB1*02:01 was the most 
prevalent (genotyped in 30.2% of patient and seroconverted group).On the other 
hand, HLA-DPB1*1801, HLA-DPB1*0202 and HLA-DPB1*0901 were rare alleles. 
The frequencies of the other alleles were given in Table 3.13. 
In German populations which are the historical control groups from our study, 
DPB1*0202was the most prevalent alleles. On the other hand, DPB1*0601, 
DPB1*1101, DPB1*0201, DPB1*1901 and DPB1*1601 were rare alleles from 
German populations. 
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When we analyze the relation of the alleles according to clinical status of the 
patients; our data demonstrate that host HLA class II genotype determines the course 
of hepatitis B infection. 
Table 3.13 : Frequencies of HLA-DPB1 alleles in our study groups 
HLA alleles Total   Group A   Group B   Group C 
 Hepatitis B 
Patients 
 Seroconverters   Historical Controls 
German 
           
N=179 AF1   N=94 AF2   N=85 AF3   AF4 
(sample size: 
47) 
AF5 
(sample size: 
100) 
DPB1*0401 29 0,162  18 0,191  11 0,129  0,09 0,06 
DPB1*0402 38 0,212   25 0,266   13 0,152   0,26 0,1 
DPB1*0201 54 0,3  21 0,223  33 0,388  0 0,01 
DPB1*1801 0 0   0 0   0 0   0,13 0,14 
DPB1*0202 0 0  0 0  0 0  0,72 0,47 
DPB1*0801 9 0,05   2 0,021   7 0,082   0,19 0,13 
DPB1*0501 2 0,011  0 0  2 0,023  0,06 0,01 
DPB1*0301 8 0,045   3 0,032   5 0,058   0,02 0,01 
DPB1*0601 2 0,011  1 0,011  1 0,011  0 0 
DPB1*1101 6 0,034   1 0,011   5 0,058   0 0 
DPB1*0101 30 0,167  19 0,2  11 0,129  0,02 0,03 
DPB1*0901 0 0   0 0   0 0   0,02 0,02 
DPB1*1001 19 0,1  5 0,053  14 0,164  0,06 0 
DPB1*1301 12 0,067   7 0,074   5 0,058   0,04 0 
DPB1*1901 1 0,006  0 0  1 0,011  0 0,01 
DPB1*1401 13 0,073   6 0,064   7 0,082   0,02 0,01 
DPB1*1501 14 0,078  1 0,011  13 0,152  0,04 0,01 
DPB1*1601 30 0,168   20 0,212   10 0,117   0 0 
DPB1*1701 17 0,09  10 0,106  7 0,082  0,04 0,01 
                        
1
: AF, frequency of all alleles.  
2
: AF, frequency of Hepatitis B patients (Group A) alleles. 
3
: AF, frequency of Control Groups (Group B) alleles. 
4,5
: AF, frequency of Historical Control (Group C) alleles (Mella et al., 1995; Jagiello 
et al., 2004). 
 
Additionaly, we have found statistically significant frequency of DPB1*15:01 allele 
was more frequent in the spontaneous seroconverted control group compared to 
chronic hepatitis B patients (15.3% vs. 1.1%, χ2=12.5, OR = 0.06, 95% CI = 0.08-
0.046 p < 0.001). DPB1*02:01 and DPB1*10:01 were the other alleles genotyped 
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more frequently found in the control group (38.8% vs. 22.3% p = 0.02 and 16.5% vs. 
5.3% p = 0.02, respectively) (Table 3.14). However these two alleles’ associations 
lost their significance after Bonferoni’s correction (pc=0.4 for all).HBsAg 
seroconversion is the ultimate target in chronic hepatitis B. This study revealed an 
association of HLA DPB1*15:01 allele with spontaneous HBsAg seroconversion. 
Table 3.14 : Comparison of frequency of HLA-DPB1 alleles between Hepatitis B 
patients group and healthy control group 
 
HLA  
Alleles 
Group A 
Hepatitis 
Patients(%) 
Group B 
Seroconverters 
(%) 
p Χ² OR 95% CI 
DPB1*0401 18(19,1) 11(12,9) 0,3 1,3 1,6 0,7-3,6 
DPB1*0402 25(26,6) 13(15,3) 0,1 3,4 2,0 0,95-
4,24 
DPB1*0201 21(22,3) 33(38,8) 0,0 5,8 0,5 0,24-
0,87 
DPB1*1801 0 0 0 0 0 - 
DPB1*0202 0 0 0 0 0 - 
DPB1*0801 2(2,1) 7(8,2) 0,1 3,5 0,2 0,05-1,2 
DPB1*0501 0 2(2,4) 0,1 2,2 0,0 - 
DPB1*0301 3(3,2) 5(5,9) 0,4 0,8 0,5 0,12-
2,28 
DPB1*0601 1(1,1 1(1,2) 0,9 0,0 0,9 0,56-
14,67 
DPB1*1101 1(1,1) 5(5,9) 0,1 3,2 0,2 0,02-
1,50 
DPB1*0101 19(20,2) 11(12,9) 0,2 1,7 1,7 0,76-
3,83 
DPB1*0901 0 0 0 0 0 - 
DPB1*1001 5(5,3) 14(16,5) 0,0 5,9 0,3 0,098-
0,829 
DPB1*1301 7(7,4) 5(5,9) 0,7 0,2 1,3 0,39-
4,22 
DPB1*1901 0 1(1,2) 0,3 1,1 0,0 - 
DPB1*1401 6(6,4) 7(8,2) 0,6 0,2 0,8 0,25-
2,36 
DPB1*1501 1(1,1) 13(15,3) <0,001 12,5 0,1 0,01-
0,47 
DPB1*1601 20(21,3) 10(11,8) 0,1 2,9 2,0 0,89-
4,62 
DPB1*1701 10(10,6) 7(8,2) 0,6 0,3 1,3 0,48-
3,66 
 
1: Based on χ2 test. P ≤ 0,05 are shown in bold; OR, odds ratio; 95% CI, confidence 
interval 
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4. CONCLUSIONS 
Chronic Hepatitis B Infection is a global health problem that affects more than 2 
billion people all around the world that can lead to chronic hepatitis, liver 
cirrhosisand hepatocellular carcinoma. Studies have shown that HLA class II 
molecules, which show high polymorphism, are the susceptibility factors of chronic 
HBV infection and related diseases.  
Recent genetic association studies have shown that  HBV infection and the 
progression of HBV infection related diseases are associated with the variations 
observed in the HLA-DP region of the genome especially HLA-DPA1 and HLA-
DPB1 region. According to previous studies, GWAS determined candidate SNPs of 
the HLA loci that are related with chronic HBV or HCV infection, hepatic fibrosis 
and hepatocellular carcinomaregion (Gebe et al., 2002; Tamori et al., 2013).   
Our study investigates the presence of possible variations in the HLA-DP region in 
Turkish population who were infected by HBV. We analysed two groups of HBV 
infected patients. A total of 94 hepatitis B patients (group A) were included and 85 
HBsAg negative, anti-HBs positive and anti–HBc IgG positive spontaneous 
seroconverted healthy subjects (group B) were also included in the study. In this line, 
our work aims to determine alterations in the HLA-DPB1 site of the genome of HBV 
infected Turkish patients and link these possible polymorphisms to disease outcome 
in Turkish population. In our study, frequencies of the 19 specific HLA-DPB1 allele 
polymorphisms were analyzed in patients with HBV infection using PCR-RFLP 
method.  
Among the 19 analyzed DPB1 alleles in this study, DPB1*0201 was the most 
prevalent (genotyped in 30.2% of all group) allele. On the other hand, HLA-
DPB1*1801, HLA-DPB1*0202 and HLA-DPB1*0901 were the rare alleles in this 
study.   
In Turkish population, our preliminary date indicated  that DPB1*1501 allele was 
more frequent allele in the spontaneous seroconverted control group compared to 
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chronic hepatitis B patients (15.3% vs. 1.1%, χ2=12.5, OR=0.06, 95% CI=0.08-0.046 
p<0.001,pc<0.001). This indicates an association of HLA DPB1*1501 allele with 
spontaneous HBsAg seroconversion. It can be speculated  that people carrying HLA-
DPB1*1501 allele may develop a resistance to Hepatitis B disease. In this study, no 
significant association between DPB1alleles of Hepatitis B infection spectrum was 
observed. 
HLA-DPB1* 1001 allele also appeared as another protective allele for HBV 
infection in our study in the begining of our analysis.On the other hand, HLA-
DPB1*1801, HLA-DPB1*0202, HLA-DPB1*0901 alleles do not appear to correlate 
with Hepatisis B Disease. 
DPB1*02:01 and DPB1*10:01 were the other alleles genotyped more frequently 
found in the control group (38.8% vs. 22.3% p = 0.02 and 16.5% vs. 5.3% p=0.02, 
respectively). However, after Bonferroni correction, only DPB1*1501 maintained its 
significance. It can be said that, presence of DPB1*1501 was the protective allele at 
Turkish population just looking at the above data without HWE analysis. 
As we didn’t have healthy control group in our study we wanted to compare results 
using historical control groups from literature. Two studies from Germany were 
selected as they belong to the same (caucasion) ethnic group with Turkish 
population. Comparisons of historical controls with our study groups showed that the 
patient group allele frequencies are more similar to historical controls and the 
seroconvertors were quite different. This can be seen in  DPB1*0201, DPB1*1001 
and DPB1*1501 alleles (which were statistically significant in chi-square test). 
DPB1* 0201 has the observation frequency of 39%  in our study, where it has the 
observation frequencies of 0% and 1% for German population historical control 
groups. DPB1*1001 has the observation frequency of 16% in our study, where it has 
the observation frequencies of 6% and 0% for German population historical control 
groups. DPB1*1501 has the observation frequency of 15% in our study, where it has 
the observation frequencies of 4% and 1% for German population historical control 
group. 
On the other hand, between our study and historical control group of German 
population, these alleles (which are not statistically significant in chi-square test) 
have similar frequencies; DPB1*0501, DPB1*0301, DPB1*0601, DPB1*0901, 
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DPB1*1901. Mentioned alleles have the following frequencies, in the respective 
order of patient group allele frequencies, seroconverted control group frequencies 
and historical group frequencies; DPB1*0501: 2%, 6%, 1%; DPB1*0301: 6%, 2%, 
1%; DPB1*0601: 1%, 0%, 0%; DPB1*0901: 0%, 2%, 2%; DPB1*1901: 1%, 0%, 
1%. 
However, between our study and historical control group of German population, 
these alleles (which are not statistically significant in chi-square test) have relatively 
different frequencies; DPB1*1801, DPB1*0202, DPB1*0101, DPB1*1601. 
Mentioned alleles have the following frequencies, in the respective order of patient 
group allele frequencies, seroconverted control group frequencies and historical 
group frequencies; DPB1*1801: 0%, 13%, 14%; DPB1*0202: 0%, 72%, 47%; 
DPB1*0101: 13%, 2%, 3%; DPB1*1601: 12%, 0%, 0%. 
Although an OR of 12,5 predicts a statistically significant frequency of HLA 
DPB1*1501 in Hepatitis B disease patients, the wide confidence interval indicates 
that more data should be collected to reach to a more definite conclusion. 
Unfortunately most of the alleles tested did not follow Hardy-Weinberg Equation, 
especially seeming significant ones including 1501 allele. Expected number of 
heterozygotes in Hardy-Weinberg analysis are two times of number of homozygotes, 
which could not be observed in our study for many genotypes. It is possible that 
 homozygotes could not be distinguished in agarose gel imaging due to too small 
distance between cutting points. The only way to distinguish is sequencing method 
and this method can reveal clearly existence of both homozygotes and  
heterozygotes. 
For future studies, to obtain more significant results, number of subjects in the 
patient group and control group should be increased. The study is evaluated for 
Turkish population and results show that, in other populations findings can be 
different. As a result, the study should be evaluated with other populations rather 
than Turkish population. In conclusion, individuals with HLA types may differ in 
susceptibilty or resistance to disease and large, multi ethnic confirmatory study is 
needed to validate these findings and further explore the genetic pathogenesis of 
HBV infection. 
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APPENDIX A 
 
LABORATORY EQUIPMENT 
 
Balances    Precisa 620C SCS 
     Precisa BJ 610C 
Centrifuges    Sigma 1-13 B. Braun International 
     Allegra 25R Centrifuge Beckman Coulter 
Electrophoresis equipments E – C mini cell primo EC320 
Gel Documentation System  UVI PhotoMW Version 99.05 for Windows 
Pipettes           Thermo Finnpipette 10 µL, 100 μl, 1000 μl 
pH meter    Mettler Toledo MP220 
Spectrophotometer   PerkinElmer Lambda25 UV/VIS Spectrometer 
Thermo cycler   Applied Biosystems GeneAmp PCR  
System 2700 
Corbett PalmCycler  
Techne FTGENE 5D 
Transilluminator    Biorad UV Transilluminator 2000 
Vortex    Herdolph Reax top  
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APPENDIX B 
 
CHEMICALS 
 
Agarose    Appli Chem 
Boric acid    Amresco 
dNTP     Fermentas 
EDTA     Appli Chem 
Ethanol    Riedel-de Haën 
SYBR     Fermentas 
MgCl2     Fermentas 
NaOH     Riedel-de Haën 
Primers    IDT DNA 
NaCl     Carlo Erba 
Tris Base    Amresco 
10X PCR Buffer   Fermentas 
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APPENDIX C 
 
BUFFERS 
 
TE Buffer  
Tris base     10 mM 
EDTA     1 mM 
Add ddH2O to 1 liter and adjust the pH to 8.0 
 
TBE (Tris-Borate-EDTA) Buffer (10X) 
Tris base    108 g  
Boric Acid    55 g 
EDTA     40 ml (0.5 M, pH 8.0) 
Add ddH2O to 1 liter and adjust the pH to 8.0 
 
Mini Agarose Gel (1%)  
Agarose    0.5 g 
TBE buffer (1X)   50 mL 
 
Midi Agarose Gel (1%)  
Agarose    1.5 g 
TBE buffer (1X)   150 mL 
 
Mini Agarose Gel (2%)  
Agarose     1.0 g 
TBE buffer (1X)   50 mL 
 
Midi Agarose Gel (2%)  
Agarose     3.0 g 
TBE buffer (1X)   150 mL 
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Mini Agarose Gel (4%)  
Agarose     2 g 
TBE buffer (1X)   50 mL 
 
Midi Agarose Gel (4%)  
Agarose    6 g 
TBE buffer (1X)   150 mL 
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APPENDIX D 
Results of PCR-RFLP gels are shown according to the patients/ controls and the 
endonuclease cleavage reactions, respectively. 
Patients and control numbers are indicated below each figure. 
FROM PATIENT GROUP 
 
 
FOKI ENZYME 
 
 
Figure D.1 Fragments detected after digestion by FokI restriction enzyme. Lanes: P: 
Pozitive control. M: size marker DNA (100-bp DNA ladder). From patient groups:2–
9 lines show each number of amplified by FokI restriction enzyme.299 base pair 
non-cleaved fragments were indicated as "0" and cleaved fragments were marked  as 
"1", showing these alleles as homozygotes. If the number consists of both celaved 
and non-cleaved fragments, this suggests the presence of heterozygotes as "0/1". 
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Figure D.2 Fragments detected after digestion by FokI restriction enzyme. Lanes: P: 
Pozitive control. M: size marker DNA (100-bp DNA ladder). From patient 
groups:18–43 lines show each number of amplified by FokI restriction enzyme.299 
base pair non-cleaved fragments were indicated as "0" and cleaved fragments were 
marked  as "1", showing these alleles as homozygotes. If the number consists of both 
celaved and non-cleaved fragments, this suggests the presence of heterozygotes as 
"0/1". 
 
 
 
Figure D.3 Fragments detected after digestion by FokI restriction enzyme. Lanes: M: 
size marker DNA (100-bp DNA ladder). From patient groups:45–55 lines show each 
number of amplified by FokI restriction enzyme.299 base pair non-cleaved fragments 
were indicated as "0" and cleaved fragments were marked  as "1", showing these 
alleles as homozygotes. If the number consists of both celaved and non-cleaved 
fragments, this suggests the presence of heterozygotes as "0/1". 
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Figure D.4 Fragments detected after digestion by FokI restriction enzyme. Lanes: 
P:Pozitive control. M: size marker DNA (100-bp DNA ladder). From patient 
groups:65–70 lines show each number of amplified by FokI restriction enzyme.299 
base pair non-cleaved fragments were indicated as "0" and cleaved fragments were 
marked  as "1", showing these alleles as homozygotes. If the number consists of both 
celaved and non-cleaved fragments, this suggests the presence of heterozygotes as 
"0/1". 
 
 
 
Figure D.5 Fragments detected after digestion by FokI restriction enzyme.Lanes: 
U:Uncut. M: size marker DNA (100-bp DNA ladder). From patient groups:65–70 
lines show each number of amplified by FokI restriction enzyme.299 base pair non-
cleaved fragments were indicated as "0" and cleaved fragments were marked  as "1", 
showing these alleles as homozygotes. If the number consists of both celaved and 
non-cleaved fragments, this suggests the presence of heterozygotes as "0/1". 
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Figure D.6 Fragments detected after digestion by FokI restriction enzyme. Lanes: 
P:Pozitive control. M: size marker DNA (100-bp DNA ladder). From patient 
groups:110–125 lines show each number of amplified by FokI restriction 
enzyme.299 base pair non-cleaved fragments were indicated as "0" and cleaved 
fragments were marked  as "1", showing these alleles as homozygotes. If the number 
consists of both celaved and non-cleaved fragments, this suggests the presence of 
heterozygotes as "0/1". 
 
 
 
 
Figure D.7 Fragments detected after digestion by FokI restriction enzyme. Lanes: N: 
Negative control. P:Pozitive control. M: size marker DNA (100-bp DNA ladder). 
From patient groups:10–109 lines show each number of amplified by FokI restriction 
enzyme.299 base pair non-cleaved fragments were indicated as "0" and cleaved 
fragments were marked  as "1", showing these alleles as homozygotes. If the number 
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consists of both celaved and non-cleaved fragments, this suggests the presence of 
heterozygotes as "0/1". 
 
 
 
AVAII ENZYME 
 
 
 
Figure D.8 Fragments detected after digestion by AvaII restriction enzyme. Lanes: 
N:Negative control. M: size marker DNA (100-bp DNA ladder). From patient 
groups:17–18 lines show each number of amplified by AvaII restriction enzyme.299 
base pair non-cleaved fragments were indicated as "0" and cleaved fragments were 
marked  as "1", showing these alleles as homozygotes. If the number consists of both 
celaved and non-cleaved fragments, this suggests the presence of heterozygotes as 
"0/1". 
 
 
 
Figure D.9 Fragments detected after digestion by AvaII restriction enzyme. Lanes: 
N:Negative control. M: size marker DNA (100-bp DNA ladder). From patient 
groups:1–85 lines show each number of amplified by AvaII restriction enzyme.299 
base pair non-cleaved fragments were indicated as "0" and cleaved fragments were 
marked  as "1", showing these alleles as homozygotes. If the number consists of both 
celaved and non-cleaved fragments, this suggests the presence of heterozygotes as 
"0/1". 
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Figure D.10 Fragments detected after digestion by AvaII restriction enzyme. Lanes: 
N:Negative control. M: size marker DNA (100-bp DNA ladder). From patient 
groups:3–26 lines show each number of amplified by AvaII restriction enzyme.299 
base pair non-cleaved fragments were indicated as "0" and cleaved fragments were 
marked  as "1", showing these alleles as homozygotes. If the number consists of both 
celaved and non-cleaved fragments, this suggests the presence of heterozygotes as 
"0/1". 
 
 
BSaJ ENZYME 
 
 
 
Figure D.11 Fragments detected after digestion by BsaJ restriction enzyme. Lanes: 
N:Negative control. M: size marker DNA (100-bp DNA ladder). From patient 
groups:7–111 lines show each number of amplified by AvaII restriction enzyme.299 
base pair non-cleaved fragments were indicated as "0" and cleaved fragments were 
marked  as "1", showing these alleles as homozygotes. If the number consists of both 
celaved and non-cleaved fragments, this suggests the presence of heterozygotes as 
"0/1". 
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Figure D.12 Fragments detected after digestion by BsaJ restriction enzyme. Lanes: 
N:Negative control. M: size marker DNA (100-bp DNA ladder). From patient 
group:2 line shows each number of amplified by AvaII restriction enzyme.Cleaved 
fragments were marked  as "1", showing these alleles as homozygotes.  
 
 
CFR13I ENZYME 
 
 
Figure D.13 Fragments detected after digestion by Cfr13I restriction enzyme. Lanes: 
N:Negative control. M: size marker DNA (100-bp DNA ladder). From patient 
groups:9–29 lines show each number of amplified by Cfr13I restriction enzyme.299 
base pair non-cleaved fragments were indicated as "0" and cleaved fragments were 
marked  as "1", showing these alleles as homozygotes. If the number consists of both 
celaved and non-cleaved fragments, this suggests the presence of heterozygotes as 
"0/1". 
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Figure D.14 Fragments detected after digestion by Cfr13I restriction enzyme. Lanes: 
N:Negative control. M: size marker DNA (100-bp DNA ladder). From patient 
groups:60–83 lines show each number of amplified by Cfr13I restriction enzyme.299 
base pair non-cleaved fragments were indicated as "0" and cleaved fragments were 
marked  as "1", showing these alleles as homozygotes. If the number consists of both 
celaved and non-cleaved fragments, this suggests the presence of heterozygotes as 
"0/1". 
 
 
 
BSP1286I ENZYME 
 
 
Figure D.15 Fragments detected after digestion by Bsp1286I restriction enzyme. 
Lanes: N:Negative control. M: size marker DNA (100-bp DNA ladder). From patient 
groups:2–24 lines show each number of amplified by Bsp1286I restriction 
enzyme.299 base pair non-cleaved fragments were indicated as "0" and cleaved 
fragments were marked  as "1", showing these alleles as homozygotes. 
 
 
Figure D.16 Fragments detected after digestion by Bsp1286I restriction enzyme. 
Lanes: N:Negative control. M: size marker DNA (100-bp DNA ladder). From patient 
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groups:2–9 lines show each number of amplified by Bsp1286I restriction 
enzyme.299 base pair non-cleaved fragments were indicated as "0" and cleaved 
fragments were marked  as "1", showing these alleles as homozygotes. 
 
Figure D.17 Fragments detected after digestion by Bsp1286I restriction enzyme. 
Lanes: N: Negative control. M, size marker DNA (100-bp DNA ladder). 
 
DdEI ENZYME 
 
 
Figure D.18 Fragments detected after digestion by DdeI restriction enzyme. Lanes: 
N:Negative control. M: size marker DNA (100-bp DNA ladder). From patient 
groups:2–9 lines show each number of amplified by DdeI restriction enzyme.299 
base pair non-cleaved fragments were indicated as "0", showing these alleles as 
homozygotes. 
 
 
 
Figure D.19 Fragments detected after digestion by DdeI restriction enzyme. Lanes: 
N:Negative control. M: size marker DNA (100-bp DNA ladder). From patient 
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groups:55–61 lines show each number of amplified by DdeI restriction enzyme.299 
base pair non-cleaved fragments were indicated as "0", showing these alleles as 
homozygotes. 
 
 
Figure D.20 Fragments detected after digestion by DdeI restriction enzyme. Lanes: 
N:Negative control. M: size marker DNA (100-bp DNA ladder). From patient 
groups:78–84 lines show each number of amplified by DdeI restriction enzyme.299 
base pair non-cleaved fragments were indicated as "0", showing these alleles as 
homozygotes. 
 
 
 
Figure D.21 Fragments detected after digestion by DdeI restriction enzyme. Lanes: 
N:Negative control. M: size marker DNA (100-bp DNA ladder). From patient 
groups:86–92 lines show each number of amplified by DdeI restriction enzyme.299 
base pair non-cleaved fragments were indicated as "0", showing these alleles as 
homozygotes. 
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BssHII ENZYME 
 
 
Figure D.22 Fragments detected after digestion by BssHII restriction enzyme. 
Lanes: N: Negative control. M: size marker DNA (100-bp DNA ladder). From 
patient groups:3–24 lines show each number of amplified by BssHII restriction 
enzyme.299 base pair non-cleaved fragments were indicated as "0" and cleaved 
fragments were marked  as "1", showing these alleles as homozygotes. If the number 
consists of both celaved and non-cleaved fragments, this suggests the presence of 
heterozygotes as "0/1". 
 
Figure D.23 Fragments detected after digestion by BssHII restriction enzyme. 
Lanes: N: Negative control. M: size marker DNA (100-bp DNA ladder). From 
patient groups:108–119 lines show each number of amplified by BssHII restriction 
enzyme.299 base pair non-cleaved fragments were indicated as "0" and cleaved 
fragments were marked  as "1", showing these alleles as homozygotes. If the number 
consists of both celaved and non-cleaved fragments, this suggests the presence of 
heterozygotes as "0/1". 
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RSA ENZYME 
 
 
Figure D.24 Fragments detected after digestion by RsaI restriction enzyme. Lanes: 
N: Negative control, from patient groups lines 181-183.  
 
 
Figure D.25 Fragments detected after digestion by RsaI restriction enzyme. Lanes: 
N: Negative control. P: Pozitive control. M: size marker DNA (100-bp DNA ladder). 
From patient groups:26–57 lines show each number of amplified by Rsa restriction 
enzyme.299 base pair non-cleaved fragments were indicated as "0" and cleaved 
fragments were marked  as "1", showing these alleles as homozygotes. If the number 
consists of both celaved and non-cleaved fragments, this suggests the presence of 
heterozygotes as "0/1". 
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Figure D.26 Fragments detected after digestion by RsaI restriction enzyme. Lanes: 
N: Negative control. P: Pozitive control. M: size marker DNA (100-bp DNA ladder). 
From patient groups:65–85 lines show each number of amplified by Rsa restriction 
enzyme.299 base pair non-cleaved fragments were indicated as "0" and cleaved 
fragments were marked  as "1", showing these alleles as homozygotes. If the number 
consists of both celaved and non-cleaved fragments, this suggests the presence of 
heterozygotes as "0/1". 
 
 
Figure D.27 Fragments detected after digestion by RsaI restriction enzyme. Lanes: 
N: Negative control. P: Pozitive control. M: size marker DNA (100-bp DNA ladder). 
From patient groups:86–110 lines show each number of amplified by Rsa restriction 
enzyme.299 base pair non-cleaved fragments were indicated as "0" and cleaved 
fragments were marked  as "1", showing these alleles as homozygotes. If the number 
consists of both celaved and non-cleaved fragments, this suggests the presence of 
heterozygotes as "0/1". 
 
Figure D.28 Fragments detected after digestion by RsaI restriction enzyme. Lanes: 
N: Negative control. P: Pozitive control. From patient groups:45–55 lines show each 
number of amplified by Rsa restriction enzyme.299 base pair non-cleaved fragments 
were indicated as "0" and cleaved fragments were marked  as "1", showing these 
76 
 
alleles as homozygotes. If the number consists of both celaved and non-cleaved 
fragments, this suggests the presence of heterozygotes as "0/1". 
 
 
EcoNI ENZYME 
 
 
Figure D.29 Fragments detected after digestion by EcoNI  restriction enzyme. 
Lanes: N: Negative control. M: size marker DNA (100-bp DNA ladder). From 
patient groups:98–118 lines show each number of amplified by EcoNI restriction 
enzyme.299 base pair non-cleaved fragments were indicated as "0" and cleaved 
fragments were marked  as "1", showing these alleles as homozygotes. If the number 
consists of both celaved and non-cleaved fragments, this suggests the presence of 
heterozygotes as "0/1". 
 
 
Figure D.30 Fragments detected after digestion by EcoNI  restriction enzyme. 
Lanes: N: Negative control. From patient groups:2–92 lines show each number of 
amplified by EcoNI restriction enzyme.299 base pair non-cleaved fragments were 
indicated as "0" and cleaved fragments were marked  as "1", showing these alleles as 
homozygotes. If the number consists of both celaved and non-cleaved fragments, this 
suggests the presence of heterozygotes as "0/1". 
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 Figure D.31 Fragments detected after digestion by EcoNI  restriction enzyme 
Lanes: N: Negative control. M, size marker DNA (100-bp DNA ladder). 
 
FROM CONTROL GROUPS 
 
FOKI ENZYME 
 
 
Figure D. Fragments detected after digestion by FokI  restriction enzyme. Lanes: N: 
Negative control. P: Pozitive control. M: size marker DNA (100-bp DNA ladder). 
From control groups:28–50 lines show each number of amplified by FokI restriction 
enzyme.299 base pair non-cleaved fragments were indicated as "0" and cleaved 
fragments were marked  as "1", showing these alleles as homozygotes. If the number 
consists of both celaved and non-cleaved fragments, this suggests the presence of 
heterozygotes as "0/1". 
 
 
Figure D.33 Fragments detected after digestion by FokI  restriction enzyme. Lanes: 
N: Negative control. P: Pozitive control. M:size marker DNA (100-bp DNA ladder). 
From control groups:123–140 lines show each number of amplified by FokI 
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restriction enzyme.299 base pair non-cleaved fragments were indicated as "0" and 
cleaved fragments were marked  as "1", showing these alleles as homozygotes. If the 
number consists of both celaved and non-cleaved fragments, this suggests the 
presence of heterozygotes as "0/1". 
 
 
 
Figure D.34 Fragments detected after digestion by FokI  restriction enzyme. Lanes: 
N: Negative control. From control groups:142-–66 lines show each number of 
amplified by FokI restriction enzyme.299 base pair non-cleaved fragments were 
indicated as "0" and cleaved fragments were marked  as "1", showing these alleles as 
homozygotes. If the number consists of both celaved and non-cleaved fragments, this 
suggests the presence of heterozygotes as "0/1". 
 
 
Figure D.35 Fragments detected after digestion by FokI  restriction enzyme. Lanes: 
N: Negative control. From control groups:124–125 lines show each number of 
amplified by FokI restriction enzyme.Cleaved fragments were marked  as "1", 
showing these alleles as homozygotes.  
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Figure D.36 Fragments detected after digestion by FokI  restriction enzyme. Lanes: 
N: Negative control. P: Pozitive control.. From control groups:40-42 lines show each 
number of amplified by FokI restriction enzyme.299 base pair non-cleaved fragments 
were indicated as "0" and cleaved fragments were marked  as "1", showing these 
alleles as homozygotes. If the number consists of both celaved and non-cleaved 
fragments, this suggests the presence of heterozygotes as "0/1". 
 
 
 
AVAII ENZYME 
 
 
Figure D.37 Fragments detected after digestion by AvaII  restriction enzyme. Lanes: 
N:Negative control. From control groups:47–52 lines show each number of amplified 
by AvaII restriction enzyme.299 base pair, cleaved fragments were marked  as 
"1"showing these alleles as homozygotes. If the number consists of both celaved and 
non-cleaved fragments, this suggests the presence of heterozygotes as "0/1". 
 
 
 
Figure D.38 Fragments detected after digestion by AvaII  restriction enzyme.. 
Lanes: N:Negative control. M: size marker DNA (100-bp DNA ladder). From control 
groups:122–140 lines show each number of amplified by AvaII restriction 
enzyme.299 base pair, showing these alleles as homozygotes. If the number consists 
of both celaved and non-cleaved fragments, this suggests the presence of 
heterozygotes as "0/1". 
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Figure D.39 Fragments detected after digestion by AvaII  restriction enzyme. Lanes: 
N:Negative control. M: size marker DNA (100-bp DNA ladder). From control 
groups:53–141 lines show each number of amplified by AvaII restriction 
enzyme.299 base pair, cleaved fragments were marked  as "1"showing these alleles 
as homozygotes. If the number consists of both celaved and non-cleaved fragments, 
this suggests the presence of heterozygotes as "0/1". 
 
 
 
Figure D.40 Fragments detected after digestion by AvaII  restriction enzyme. Lanes: 
N:Negative control. M: From control groups:182–183 lines show each number of 
amplified by AvaII restriction enzyme.299 base pair, cleaved fragments were marked  
as "1"showing these alleles as homozygotes. If the number consists of both celaved 
and non-cleaved fragments, this suggests the presence of heterozygotes as "0/1". 
 
BSAJ ENZYME 
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Figure D.41 Fragments detected after digestion by BsaJI  restriction enzyme. Lanes: 
N:Negative control. From comtrol groups:45–65 lines show each number of 
amplified by BsaJ restriction enzyme.299 base pair non-cleaved fragments were 
indicated as "0" and cleaved fragments were marked  as "1", showing these alleles as 
homozygotes. If the number consists of both celaved and non-cleaved fragments, this 
suggests the presence of heterozygotes as "0/1". 
 
 
Figure D.42 Fragments detected after digestion by BsaJI  restriction enzyme. Lanes: 
N:Negative control. P:Pozitive control. From control groups:143–161 lines show 
each number of amplified by BsaJ restriction enzyme.299 base pair non-cleaved 
fragments were indicated as "0" and cleaved fragments were marked  as "1", showing 
these alleles as homozygotes. If the number consists of both celaved and non-cleaved 
fragments, this suggests the presence of heterozygotes as "0/1". 
 
 
 
 
CFR13I ENZYME 
 
 
 
Figure D.43 Agarose gel electrophoresis analysis on 2.0% agarose gel of PCR-RFLP 
methods from blood samples. Lanes: N:Negative control. From control groups:142–
66 lines show each number of amplified by Cfr13I restriction enzyme.299 base pair 
non-cleaved fragments were indicated as "0" and cleaved fragments were marked  as 
"1", showing these alleles as homozygotes. If the number consists of both celaved 
and non-cleaved fragments, this suggests the presence of heterozygotes as "0/1". 
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Figure D.44 Fragments detected after digestion by BsaJI  restriction enzyme. Lanes: 
N:Negative control. From control groups:166–170 lines show each number of 
amplified by Cfr13I restriction enzyme.299 base pair non-cleaved fragments were 
indicated as "0" and cleaved fragments were marked  as "1", showing these alleles as 
homozygotes. If the number consists of both celaved and non-cleaved fragments, this 
suggests the presence of heterozygotes as "0/1". 
 
Figure D.45 Fragments detected after digestion by BsaJI  restriction enzyme. Lanes: 
N:Negative control. From control groups:171–177 lines show each number of 
amplified by Cfr13I restriction enzyme.299 base pair non-cleaved fragments were 
indicated as "0" and cleaved fragments were marked  as "1", showing these alleles as 
homozygotes. If the number consists of both celaved and non-cleaved fragments, this 
suggests the presence of heterozygotes as "0/1". 
 
Figure D.46 Fragments detected after digestion by BsaJI  restriction enzyme. Lanes: 
N:Negative control. From control groups:171–172 lines show each number of 
amplified by Cfr13I restriction enzyme.299 base pair non-cleaved fragments were 
indicated as "0" and cleaved fragments were marked  as "1", showing these alleles as 
homozygotes. If the number consists of both celaved and non-cleaved fragments, this 
suggests the presence of heterozygotes as "0/1". 
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BSP1286I ENZYME 
 
 
 
Figure D.47 Fragments detected after digestion by Bsp1286I  restriction enzyme. 
Lanes: N:Negative control. M: size marker DNA (100-bp DNA ladder). From control 
groups:27–50 lines show each number of amplified by Bsp1286I restriction 
enzyme.299 base pair non-cleaved fragments were indicated as "0" and cleaved 
fragments were marked  as "1", showing these alleles as homozygotes.If the number 
consists of both celaved and non-cleaved fragments, this suggests the presence of 
heterozygotes as "0/1". 
 
 
Figure D.48 Fragments detected after digestion by Bsp1286I  restriction enzyme. 
Lanes: N:Negative control. From control groups:122–140 lines show each number of 
amplified by Bsp1286I restriction enzyme.299 base pair non-cleaved fragments were 
indicated as "0" and cleaved fragments were marked  as "1", showing these alleles as 
homozygotes.If the number consists of both celaved and non-cleaved fragments, this 
suggests the presence of heterozygotes as "0/1". 
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Figure D.49 Fragments detected after digestion by Bsp1286I  restriction enzyme. 
Lanes: P:Pozitive control. From control groups:36–43 lines show each number of 
amplified by Bsp1286I restriction enzyme.299 base pair non-cleaved fragments were 
indicated as "0" and cleaved fragments were marked  as "1", showing these alleles as 
homozygotes. If the number consists of both celaved and non-cleaved fragments, this 
suggests the presence of heterozygotes as "0/1". 
 
 
Figure D.50 Fragments detected after digestion by Bsp1286I  restriction enzyme. 
Lanes: N:Negative control. From control groups:133–183 lines show each number of 
amplified by Bsp1286I restriction enzyme.299 base pair non-cleaved fragments were 
indicated as "0" and cleaved fragments were marked  as "1", showing these alleles as 
homozygotes. 
 
DdeI ENZYME 
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Figure D.51 Fragments detected after digestion by DdeI  restriction enzyme. Lanes: 
N:Negative control. From control groups:122–140 lines show each number of 
amplified by DdeI restriction enzyme.299 base pair non-cleaved fragments were 
indicated as "0", showing these alleles as homozygotes. If the number consists of 
both celaved and non-cleaved fragments, this suggests the presence of heterozygotes 
as "0/1". 
 
 
Figure D.52 Fragments detected after digestion by DdeI  restriction enzyme. Lanes: 
N:Negative control. From control groups:172–183 lines show each number of 
amplified by DdeI restriction enzyme.299 base pair non-cleaved fragments were 
indicated as "0", showing these alleles as homozygotes.  
 
BSSHII ENZYME 
 
 
 
Figure D.53 Fragments detected after digestion by BssHII restriction enzyme. 
Lanes: N: Negative control. From control groups:122–140 lines show each number 
of amplified by BssHII restriction enzyme.299 base pair non-cleaved fragments were 
indicated as "0" and cleaved fragments were marked  as "1", showing these alleles as 
homozygotes. If the number consists of both celaved and non-cleaved fragments, this 
suggests the presence of heterozygotes as "0/1". 
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Figure D.54 Fragments detected after digestion by BssHII restriction enzyme. 
Lanes: N: Negative control. From control groups:45–62 lines show each number of 
amplified by BssHII restriction enzyme.299 base pair non-cleaved fragments were 
indicated as "0" and cleaved fragments were marked  as "1", showing these alleles as 
homozygotes. If the number consists of both celaved and non-cleaved fragments, this 
suggests the presence of heterozygotes as "0/1". 
 
RSA ENZYME 
 
 
Figure D.55 Fragments detected after digestion by RsaI restriction enzyme. Lanes: 
N: Negative control. From control groups:28–65 lines show each number of 
amplified by Rsa restriction enzyme.299 base pair non-cleaved fragments were 
indicated as "0" and cleaved fragments were marked  as "1", showing these alleles as 
homozygotes. If the number consists of both celaved and non-cleaved fragments, this 
suggests the presence of heterozygotes as "0/1". 
 
Figure D.56 Fragments detected after digestion by RsaI restriction enzyme. Lanes: 
N: Negative control. From control groups:122–141 lines show each number of 
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amplified by Rsa restriction enzyme.299 base pair non-cleaved fragments were 
indicated as "0" and cleaved fragments were marked  as "1", showing these alleles as 
homozygotes. If the number consists of both celaved and non-cleaved fragments, this 
suggests the presence of heterozygotes as "0/1". 
 
 
Figure D.57 Fragments detected after digestion by RsaI restriction enzyme. Lanes: 
N: Negative control. From control groups:142–161 lines show each number of 
amplified by Rsa restriction enzyme.299 base pair non-cleaved fragments were 
indicated as "0" and cleaved fragments were marked  as "1", showing these alleles as 
homozygotes. If the number consists of both celaved and non-cleaved fragments, this 
suggests the presence of heterozygotes as "0/1". 
 
 
Figure D.58 Fragments detected after digestion by RsaI restriction enzyme. Lanes: 
N: Negative control. From control groups:181–183 lines show each number of 
amplified by Rsa restriction enzyme.299 base pair non-cleaved fragments were 
indicated as "0" and cleaved fragments were marked  as "1", showing these alleles as 
homozygotes. If the number consists of both celaved and non-cleaved fragments, this 
suggests the presence of heterozygotes as "0/1". 
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EcoNI ENZYME 
 
 
Figure D.59 Fragments detected after digestion by EcoNI restriction enzyme. Lanes: 
N: Negative control. M: size marker DNA (100-bp DNA ladder). From control 
groups:28–44 lines show each number of amplified by EcoNI restriction enzyme.299 
base pair non-cleaved fragments were indicated as "0" and cleaved fragments were 
marked  as "1", showing these alleles as homozygotes. If the number consists of both 
celaved and non-cleaved fragments, this suggests the presence of heterozygotes as 
"0/1". 
 
 
Figure D.60 Fragments detected after digestion by EcoNI restriction enzyme. Lanes: 
N: Negative control. M: size marker DNA (100-bp DNA ladder). From control 
groups:45–62 lines show each number of amplified by EcoNI restriction enzyme.299 
base pair non-cleaved fragments were indicated as "0" and cleaved fragments were 
marked  as "1", showing these alleles as homozygotes. If the number consists of both 
celaved and non-cleaved fragments, this suggests the presence of heterozygotes as 
"0/1". 
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Figure D.61 Fragments detected after digestion by EcoNI restriction enzyme. Lanes: 
N: Negative control. From control groups:122–140 lines show each number of 
amplified by EcoNI restriction enzyme.299 base pair non-cleaved fragments were 
indicated as "0" and cleaved fragments were marked  as "1", showing these alleles as 
homozygotes. If the number consists of both celaved and non-cleaved fragments, this 
suggests the presence of heterozygotes as "0/1". 
 
 
Figure D.62 Fragments detected after digestion by EcoNI restriction enzyme. Lanes: 
N: Negative control. From control groups:181–183 lines show each number of 
amplified by EcoNI restriction enzyme.299 base pair non-cleaved fragments were 
indicated as "0" and cleaved fragments were marked  as "1", showing these alleles as 
homozygotes. If the number consists of both celaved and non-cleaved fragments, this 
suggests the presence of heterozygotes as "0/1". 
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APPENDIX E 
E.1Lists of PatientGroup with  DPB1 Alleles 
 
 
 
 
 
 
 
 
 
 
 
 
 
Patient No DPB1 Allels Patient No DPB1 Allels Patient No DPB1 Allels Patient No DPB1 Allels
2 0402/1501 36 0401/0401 69 0402/0402 98 1701/0402
3 0402/0201 38 0401/0201 70 0201 100 0402/0201
6 1601/1601 39 0401/0201 71 0401/0201 101 0402
7 1601 42 1601/0101 72 0401/0401 103 1701/0402
8 0601/1401 43 1001/1301 73 1701/0301 104 0402/0402
9 0402/0402 45 0402/0201 74 0201/0201 105 0402
10 0402/0402 49 1601/1601 75 0402/0201 108 1601/0402
11 0101 51 0402/0201 77 0401 109 0101/0101
12 0401/0401 52 0201/0201 78 0101/0101 110 0101
13 0401 53 1001/1401 79 0101 111 1601/1601
14 0201/0101 54 0402/0201 81 1401/0101 113 1601/1601
15 0101/1301 55 1601/0301 82 0101/0101 114 0402
17 1701/0401 56 0201/0201 83 1401/0101 115 1601/1601
18 0101/1401 57 0301/1001 84 1401/0101 116 1601/1601
19 0101/0101 59 0201/0201 85 1701/0402 117 1601/1601
21 0201/0201 60 0401/0401 86 1601/1601 118 0402/0201
22 0101/1301 61 1601/1301 87 1601/1601 120 0101/0101
23 0402/1701 62 1701/0401 88 1601/1601 121 1601/1301
24 0401/0401 63 0401/0401 89 1601/1601 122 1701/0402
26 0402/0201 64 0402/0201 91 0801/0801 123 1701/0401
27 0801/0801 65 0401/0201 92 1701/1401 124 0401/1001
29 0101 66 1001/1301 93 1601/1601 125 1101/0101
30 0401/0401 67 1601/1601 95 1601/0301
35 0402/0201 68 0402/0402 97 0101/0101
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E.2 Lists of control group with DPB1 alleles 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Control No DPB1 Allels Control No DPB1 Allels Control No DPB1 Allels Control No DPB1 Allels
27 1101 53 0402/0301 137 1001/0101 171 1601/1401
28 1601/1701 54 0201/1501 138 0101 172 0801
30 0401/0402 55 1001 139 1001 173 0402/1701
31 0201/0402 56 0101/1001 140 1001 174 0201/1501
32 0402 58 0201 141 1601 175 0401/1701
34 0201 59 0201 143 0201/0801 176 0201/1501
35 0201 60 0301/1001 145 1601/1301 177 0401/0201
36 0501 61 0201/1501 147 1401/0402 178 1701/0401
37 0101/0402 62 0201/1501 148 1001/0201 179 0201/1501
38 0301/1301 63 1001/1501 149 0201 180 0201/1101
39 0201/1501 64 1601/1101 150 0201 181 0401/0201
40 0201/1501 65 1301/1601 153 0201 182 0402/1401
41 0201 66 1601/1101 154 1001 183 0401/1701
42 0201 122 0801/0101 157 1601/0201
43 0201/0402 123 0501/0601 159 1601/1001
44 0402/0801 125 0201/1001 161 0101
45 0201/1501 126 0101/0801 162 1401/1101
46 0201 127 0101/0801 163 1401/0401
47 0201 128 1401/0401 164 0201/1501
48 0402/1001 129 0301/0101 165 1001/1501
49 0401/0402 130 1301/1601 166 0201/1501
50 0201 131 1001/0101 167 0201
51 0401/1301 134 1301/1901 168 0402/1401
52 0401/0201 135 1601/0101 169 0201
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APPENDIX F 
 
ENZYMES 
 
DreamTaq DNA Polymerase  Fermentas 
 
      Invitrogen 
 
 
 
Bsp12861, FokI, DdeI , BsaJIFermantas 
BssHII, Cfrl31RsaI, EcoNISacem 
AvaII 
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APPENDIX G 
MARKERS 
 
O’Gene RulerTM DNA Ladder Low Range  Fermentas 
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O’Gene RulerTM DNA Ladder Ultra Low Range  Fermentas 
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